

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
13 December 2001 (13.12.2001)

PCT

(10) International Publication Number  
WO 01/94420 A1

- (51) International Patent Classification<sup>7</sup>: C07K 17/00, C12N 5/06, A61K 35/34
- (74) Agent: WHITE, John, P.; Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY 10036 (US).
- (21) International Application Number: PCT/US01/18399
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 5 June 2001 (05.06.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 09/587,441 5 June 2000 (05.06.2000) US
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:  
US 09/587,441 (CIP)  
Filed on 5 June 2000 (05.06.2000)
- (71) Applicant (*for all designated States except US*): THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK [US/US]; West 116th Street and Broadway, New York, NY 10027 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): ITESCU, Silviu [AU/US]; Apartment 12E, 279 East 44th Street, New York, NY 10017 (US).
- Published:  
— with international search report  
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IDENTIFICATION AND USE OF HUMAN BONE MARROW-DERIVED ENDOTHELIAL PROGENITOR CELLS TO IMPROVE MYOCARDIAL FUNCTION AFTER ISCHEMIC INJURY

(57) Abstract: The present invention provides a method of stimulating vasculogenesis of myocardial infarct damaged tissue in a subject comprising: (a) removing stem cells from a location in the subject; (b) recovering endothelial progenitor cells in the stem cells; (c) introducing the endothelial progenitor cells from step (b) into a different location in the subject such that the precursors migrate to and stimulate revascularization of the tissue. The stem cells may be removed directly or by mobilization. The endothelial progenitor cells may be expanded before introduction into the subject. The present invention further provides a method of inducing angiogenesis in peri-infarct tissue. The present invention further provides a method of selectively increasing the trafficking of human bone marrow-derived endothelial cell precursors to the site of tissue damaged by ischemic injury which comprises: (a) administering endothelial progenitor cells to a subject; (b) administering chemokines to the subject so as to thereby attract endothelial cell precursors to the ischemic tissue. The present invention provides a method of stimulating vasculogenesis or angiogenesis of myocardial infarct damaged tissue in a subject comprising injecting allogeneic stem cells into a subject. The present invention further provides a method of improving myocardial function in a subject that has suffered a myocardial infarct comprising any of the instant methods. The present invention further provides a method of improving myocardial function in a subject that has suffered a myocardial infarct comprising injecting G-CSF or anti-CXCR4 antibody into the subject in order to mobilize endothelial progenitor cells.

WO 01/94420 A1

**IDENTIFICATION AND USE  
OF HUMAN BONE MARROW-DERIVED ENDOTHELIAL PROGENITOR  
CELLS TO IMPROVE MYOCARDIAL FUNCTION AFTER ISCHEMIC  
INJURY**

This application is a continuation-in-part and claims priority of U.S. Serial No. 09/587,441, filed June 5, 2000, the contents of which are hereby incorporated by reference.

5 Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entirety are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic citation  
10 for these references may be found at the end of this application, preceding the claims.

**BACKGROUND OF THE INVENTION**

15 Left ventricular remodeling after myocardial infarction is a major cause of subsequent heart failure and death. The capillary network cannot keep pace with the greater demands of the hypertrophied but viable myocardium, resulting in myocardial death and fibrous replacement. The first series of  
20 experiments of the present invention, described below, show that human adult bone marrow contains endothelial cell precursors with phenotypic and functional characteristics of embryonic hemangioblasts, and that these can be mobilized, expanded, and used to induce infarct bed vasculogenesis after

experimental myocardial infarction. The neo-angiogenesis results in significant and sustained increase in viable myocardial tissue, reduction in collagen deposition, and improved myocardial function. The use of cytokine-mobilized autologous human bone marrow-derived angioblasts for revascularization of myocardial infarct tissue, alone or in conjunction with currently used therapies, offers the potential to significantly reduce morbidity and mortality associated with left ventricular remodeling post-myocardial infarction.

Although prompt reperfusion within a narrow time window has significantly reduced early mortality from acute myocardial infarction, post-infarction heart failure is increasing and reaching epidemic proportions (1). Left ventricular remodeling after myocardial infarction, characterized by expansion of the initial infarct area, progressive thinning of the wall surrounding the infarct, and dilation of the left ventricular lumen, has been identified as a major prognostic factor for subsequent heart failure (2,3). This process is accompanied by transcription of genes normally expressed only in the fetal state, rapid and progressive increase in collagen secretion by cardiac fibroblasts, deposition of fibrous tissue in the ventricular wall, increased wall stiffness, and both diastolic and systolic dysfunction (4,5). Hypoxia directly stimulates collagen secretion by cardiac fibroblasts, while inhibiting DNA synthesis and cellular proliferation (6). In animal models, late reperfusion following experimental myocardial infarction at a point

beyond myocardial salvage significantly benefits remodeling (7). Moreover, the presence of a patent infarct related artery is consistently associated with survival benefits in the post-infarction period in humans (8). This appears to be  
5 due to adequate reperfusion of the infarct vascular bed which modifies the ventricular remodeling process and prevents abnormal changes in wall motion (9).

Successful reperfusion of non-cardiac tissues rendered  
10 ischemic in experimental animal models has recently been demonstrated by use of either circulating or bone marrow-derived cellular elements (10-13). Although the precise nature of these cells was not defined in these studies, the presence of precursor cells in both adult human circulation  
15 and bone marrow which have the capability to differentiate into functional endothelial cells, a process termed vasculogenesis (14-16), has been shown. In the pre-natal period, precursor cells derived from the ventral endothelium of the aorta in human and lower species have been shown to  
20 give rise to cellular elements involved in both the processes of vasculogenesis and hematopoiesis (17,18). These cells have been termed embryonic hemangioblasts, are characterized by expression of CD34, CD117 (stem cell factor receptor), Flk-1 (vascular endothelial cell growth factor receptor-2,  
25 VEGFR-2), and Tie-2 (angiopoietin receptor), and have been shown to have high proliferative potential with blast colony formation in response to VEGF (19-22). The subsequent proliferation and differentiation of embryonic hemangioblasts to adult-type pluripotent stem cells appears to be related to

co-expression of the GATA-2 transcription factor, since GATA-2 knockout embryonic stem cells have a complete block in definitive hematopoiesis and seeding of the fetal liver and bone marrow (23). Moreover, the earliest precursor of both hematopoietic and endothelial cell lineage to have diverged from embryonic ventral endothelium has been shown to express VEGF receptors as well as GATA-2 and alpha4-integrins (24). The first series of experiments of the present invention shows that GATA-2 positive stem cell precursors are also present in adult human bone marrow, demonstrate properties of hemangioblasts, and can be used to induce vasculogenesis, thus preventing remodeling and heart failure in experimental myocardial infarction.

Growth of new vessels from pre-existing mature endothelium has been termed angiogenesis, and can be regulated by many factors including certain CXC chemokines (47-50). In contrast, vasculogenesis is mediated by bone marrow-derived endothelial precursors (51-53) with phenotypic characteristics of embryonic angioblasts and growth/differentiation properties regulated by receptor tyrosine kinases such as vascular endothelial growth factor (VEGF) (54-57). Therapeutic vasculogenesis (58-61) has the potential to improve perfusion of ischemic tissues, however the receptor/ligand interactions involved in selective trafficking of endothelial precursors to sites of tissue ischemia are not known. The second series of experiments of the present invention, described below, show that vasculogenesis can develop in infarcted myocardium as a

result of interactions between CXC receptors on human bone marrow-derived angioblasts and ELR-positive CXC chemokines induced by ischemia, including IL-8 and Gro-alpha. Moreover, redirected trafficking of angioblasts from the bone marrow to ischemic myocardium can be achieved by blocking CXCR4/SDF-1 interactions, resulting in increased vasculogenesis, decreased myocardial death and fibrous replacement, and improved cardiac function. The results of the experiments indicate that CXC chemokines, including IL-8, Gro-alpha, and stromal-derived factor-1 (SDF-1), play a central role in regulating vasculogenesis in the adult human, and suggest that manipulating interactions between CXC chemokines and their receptors on bone marrow-derived angioblasts can lead to optimal therapeutic vasculogenesis and salvage of ischemic tissues. The third series of experiments, described below, show that CC chemokines also play a role in mediating angioblast chemotaxis to ischemic myocardium.

The angiogenic response during wound repair or inflammation is thought to result from changes in adhesive interactions between endothelial cells in pre-existing vasculature and extracellular matrix which are regulated by locally-produced factors and which lead to endothelial cell migration, proliferation, reorganization and microvessel formation (70). The human CXC chemokine family consists of small (<10 kD) heparin-binding polypeptides that bind to and have potent chemotactic activity for endothelial cells. Three amino acid residues at the N-terminus (Glu-Leu-Arg, the ELR motif) determine binding of CXC chemokines such as IL-8 and Gro-

alpha to CXC receptors 1 and 2 on endothelial cells (49,71), thus promoting endothelial chemotaxis and angiogenesis (47-48). In contrast, CXC chemokines lacking the ELR motif bind to different CXC receptors and inhibit growth-factor mediated angiogenesis (49-72). Although SDF-1, an ELR-negative CXC chemokine, is a potent inducer of endothelial chemotaxis through interactions with CXCR4 (73), its angiogenic effects appear to be limited to the developing gastrointestinal tract vascular system (50).

10

Vasculogenesis first occurs during the pre-natal period, with haemangioblasts derived from the human ventral aorta giving rise to both endothelial and haematopoietic cellular elements (74,75). Similar endothelial progenitor cells have recently been identified in adult human bone marrow (51-53), and shown to have the potential to induce vasculogenesis in ischemic tissues (59-61). However, the signals from ischemic sites required for chemoattraction of such bone marrow-derived precursors, and the receptors used by these cells for selective trafficking to these sites, are unknown. Following myocardial infarction a process of neoangiogenesis occurs (62,63); but is insufficient to sustain viable tissue undergoing compensatory hypertrophy, leading to further cell death, expansion of the initial infarct area, and collagen replacement (64-66). This process, termed remodeling, results in progressive heart failure (67-69). In the experiments described below, a nude rat model of myocardial infarction was used to investigate whether CXC chemokines containing the ELR motif regulate migration of human bone

25

marrow-derived angioblasts to sites of tissue ischemia. Moreover, since selective bone marrow homing and engraftment of haematopoietic progenitors depends on CXCR4 binding to SDF-1 expressed constitutively in the bone marrow (76-78), whether interruption of CXCR4/SDF-1 interactions could redirect trafficking of human bone marrow-derived angioblasts to sites of tissue ischemia, thereby augmenting therapeutic vasculogenesis, was examined. The results of the experiments indicate that CXC chemokines, including IL-8, Gro-alpha, and SDF-1, play a central role in regulating human adult bone marrow-dependent vasculogenesis. Further, the fourth series of experiments described below show that stem cells can induce angiogenesis in peri-infarct tissue.



SUMMARY OF THE INVENTION

This invention provides a method of stimulating vasculogenesis in ischemia-damaged tissue of a subject comprising:

- 5                   (a) removing stem cells from a location within the subject;
- (b) recovering endothelial progenitor cells from the stem cells removed in step (a); and
- 10                  (c) introducing the endothelial progenitor cells from step (b) into a different location within the subject such that the endothelial progenitor cells stimulate vasculogenesis in the subject's ischemia-damaged tissue.

15       This invention also provides the instant method, wherein subsequent to step (b), but before step (c), the endothelial progenitor cells are expanded by contacting them with a growth factor.

20       This invention also provides the instant method, wherein the growth factor is a cytokine.

          This invention also provides the instant method, wherein the cytokine is VEGF, FGF, G-CSF, IGF, M-CSF, or GM-CSF.

25       This invention also provides the instant method, wherein the growth factor is a chemokine.

          This invention also provides the instant method, wherein the

chemokine is Interleukin-8.

This invention also provides the instant method, wherein the endothelial progenitor cells are separated from other stem  
5 cells before expansion.

This invention also provides the instant method, wherein the ischemia-damaged tissue is myocardium.

10 This invention also provides the instant method, wherein the ischemia-damaged tissue is nervous system tissue.

This invention also provides the instant method, wherein the stem cells are removed from the subject's bone marrow.

15 This invention also provides the instant method, wherein the removal of the stem cells from the bone marrow is effected by aspiration from the subject's bone marrow.

20 This invention also provides the instant method, wherein the removal of the stem cells from the subject is effected by a method comprising:

- 25
- (a) introducing a growth factor into the subject to mobilize the stem cells into the subject's blood; and
  - (b) removing a sample of blood containing the stem cells from the subject.

This invention also provides the instant method, wherein the

growth factor is introduced into the subject subcutaneously, orally, intravenously or intramuscularly.

5 This invention also provides the instant method, wherein the growth factor is a chemokine that induces mobilization.

This invention also provides the instant method, wherein the chemokine is Interleukin-8.

10 This invention also provides the instant method, wherein the growth factor is a cytokine.

This invention also provides the instant method, wherein the cytokine is G-CSF, M-CSF, or GM-CSF.

15 This invention also provides the instant method, wherein the endothelial progenitor cells are recovered based upon their expression of CD117.

20 This invention also provides the instant method, wherein the endothelial progenitor cells are recovered based upon their expression of a GATA-2 activated gene product.

25 This invention also provides the instant method, wherein the endothelial progenitor cells are recovered based upon their expression of one or more of CD34, VEGF-R, Tie-2, GATA-3 or AC133.

This invention also provides the instant method, wherein the

subject has suffered or is suffering from one or more of the following: myocardial infarction, chronic heart failure, ischemic heart disease, coronary artery disease, diabetic heart disease, hemorrhagic stroke, thrombotic stroke, embolic stroke, limb ischemia, or another disease in which tissue is rendered ischemic.

This invention also provides the instant method, wherein step (a) occurs prior to the subject suffering ischemia-damaged tissue and wherein step (c) occurs after the subject has suffered ischemia-damaged tissue.

This invention also provides the instant method, wherein the endothelial progenitor cells are frozen for a period of time between steps (b) and (c).

This invention also provides the instant method, wherein the endothelial progenitor cells are frozen for a period of time after being expanded but before step (c) is performed.

This invention also provides the instant method, wherein the endothelial progenitor cells are introduced into the subject by injection directly into the peripheral circulation, heart muscle, left ventricle, right ventricle, coronary artery, cerebro-spinal fluid, neural tissue, ischemic tissue, or post-ischemic tissue.

This invention also provides the instant method, further comprising administering to the subject one or more of the

following: an inhibitor of Plasminogen Activator Inhibitor, Angiotensin Converting Enzyme Inhibitor or a beta blocker, wherein such administration occurs prior to, concomitant with, or following step (c).

5

This invention also provides a method of stimulating angiogenesis in peri-infarct tissue in a subject comprising:

- (a) removing stem cells from a location within a subject;
- 10 (b) recovering endothelial progenitor cells from the stem cells removed in step (a);
- (c) expanding the endothelial progenitor cells recovered in step (b) by contacting the progenitor cells with a growth factor; and
- 15 (d) introducing the expanded endothelial progenitor cells from step (c) into a different location in the subject such that the endothelial progenitor cells stimulate angiogenesis in peri-infarct tissue in the
- 20 subject.

This invention also provides a method of selectively increasing the trafficking of endothelial progenitor cells to ischemia-damaged tissue in a subject comprising:

- 25 (a) administering endothelial progenitor cells to a subject; and
- (b) administering a chemokine to the subject so as to thereby attract the endothelial progenitor cells to the ischemia-damaged tissue.

This invention also provides the instant method, wherein the chemokine is administered to the subject prior to administering the endothelial progenitor cells.

- 5 This invention also provides the instant method, wherein the chemokine is administered to the subject concurrently with the endothelial progenitor cells.

- 10 This invention also provides the instant method, wherein the chemokine is administered to the subject after administering the endothelial progenitor cells.

- 15 This invention also provides the instant method, wherein the chemokine is a CXC chemokine.

This invention also provides the instant method, wherein the CXC chemokine is selected from the group consisting of Interleukin-8, Gro-Alpha, or Stromal-Derived Factor-1.

- 20 This invention also provides the instant method, wherein the chemokine is a CC chemokine.

- 25 The method of claim 34, wherein the CC chemokine is selected from the group consisting of RANTES, EOTAXIN, MCP-1, MCP-2, MCP-3, or MCP-4.

This invention also provides the instant method, wherein the chemokine is administered to the subject by injection into the subject's peripheral circulation, heart muscle, left

ventricle, right ventricle, coronary arteries, cerebro-spinal fluid, neural tissue, ischemic tissue, or post-ischemic tissue.

5 This invention also provides a method of increasing trafficking of endothelial progenitor cells to ischemia-damaged tissue in a subject comprising inhibiting any interaction between Stromal-Derived Factor-1 and CXCR4.

10 This invention also provides the instant method, wherein interaction between Stromal-Derived Factor-1 (SDF-1) and CXCR4 is inhibited by administration of an anti-SDF-1 or an anti-CXCR4 monoclonal antibody to the subject.

15 This invention also provides the instant method, further comprising administering to the subject an angiotensin converting enzyme inhibitor, an AT<sub>1</sub>-receptor blocker, or a beta blocker.

20 This invention also provides a method of reducing trafficking of endothelial progenitor cells to bone marrow in a subject comprising inhibiting production of Stromal-Derived Factor-1 in the subject's bone marrow.

25 This invention also provides the instant method, wherein SDF-1 production is inhibited by administration of an anti-SDF-1 or anti-CXCR4 monoclonal antibody to the subject.

This invention also provides a method for treating a cancer

in a subject comprising administering to the subject a monoclonal antibody directed against an epitope of a specific chemokine produced by proliferating cells associated with the cancer so as to reduce trafficking of endothelial progenitor cells to such proliferating cells and thereby treat the cancer in the subject.

This invention also provides a method for treating a cancer in a subject comprising administering to the subject a monoclonal antibody directed against an epitope of a specific receptor located on an endothelial progenitor cell, for a chemokine produced by proliferating cells associated with the cancer, so as to reduce trafficking of the endothelial progenitor cell to such proliferating cells and thereby treat the cancer in the subject.

This invention also provides a method for treating a tumor in a subject comprising administering to the subject an antagonist to a specific receptor on an endothelial progenitor cell so as to reduce the progenitor cell's ability to induce vasculogenesis in the subject's tumor and thereby treat the tumor.

This invention also provides a method for treating a tumor in a subject comprising administering to the subject an antagonist to a specific receptor on an endothelial progenitor cell so as to reduce the progenitor cell's ability to induce angiogenesis in the subject's tumor and thereby treat the tumor.



This invention also provides the instant method, wherein the receptor is a CD117 receptor.

5 This invention also provides a method for expressing a gene of interest in an endothelial progenitor cell or a mast progenitor cell which comprises inserting into the cell a vector comprising a promoter containing a GATA-2 motif and the gene of interest.

10 This invention also provides the instant method, wherein the vector is inserted into the cell by transfection.

This invention also provides the instant method, wherein the promoter is a preproendothelin-1 promoter.

15

This invention also provides the instant method, wherein the promoter is of mammalian origin.

20 This invention also provides the instant method, wherein the promoter is of human origin.

25 This invention provides a composition comprising an amount of a monoclonal antibody directed against an epitope of a specific chemokine produced by a cancer effective to reduce trafficking of endothelial progenitor cells to the cancer, and a pharmaceutically acceptable carrier.

This invention provides a method of treating an abnormality in a subject wherein the abnormality is treated by the

expression of a GATA-2 activated gene product in the subject comprising:

- (a) removing stem cells from a location within the subject;
- 5 (b) recovering endothelial progenitor cells from the stem cells removed in step (a);
- (c) recovering those endothelial progenitor cells recovered in step (b) that express GATA-2;
- 10 (d) inducing the cells recovered in step (c) as expressing GATA-2 to express a GATA-2 activated gene product; and
- 15 (e) introducing the cells expressing a GATA-2 activated gene product from step (d) into a different location in the subject such as to treat the abnormality.

This invention provides a method of treating an abnormality in a subject wherein the abnormality is treated by the expression of a GATA-2 activated gene product in the subject comprising:

- (a) removing stem cells from a location within the subject;
- (b) recovering mast progenitor cells from the stem cells removed in step (a);
- 25 (c) recovering those mast progenitor cells recovered in step (b) that express GATA-2;
- (d) inducing the cells recovered in step (c) as expressing GATA-2 to express a GATA-2 activated gene product; and

- (e) introducing the cells expressing a GATA-2 activated gene product from step (d) into a different location in the subject such as to treat the abnormality

5

This invention provides the instant method, wherein the abnormality is ischemia-damaged tissue.

This invention provides the instant method, wherein the gene product is proendothelin.

10

This invention provides the instant method, wherein the gene product is endothelin.

This invention provides the a method of improving myocardial function in a subject that has suffered a myocardial infarct comprising:

15

(a) removing stem cells from a location in the subject;

20

(b) recovering cells that express CD117 from the stem cells; and

(c) introducing the recovered cells into a different location in the subject such that the cells improve myocardial function in the subject.

25

This invention provides the instant methods, wherein the subject is of mammalian origin.

This invention provides the instant method, wherein the mammal is of human origin.

This invention also provides a method of stimulating  
5 vasculogenesis in ischemia-damaged tissue in a subject comprising:

- (a) obtaining allogeneic stem cells;
- (b) recovering endothelial progenitor cells from the stem cells removed in step (a); and
- 10 (c) introducing the endothelial progenitor cells recovered in step (b) into the subject such that the endothelial progenitor cells stimulate vasculogenesis in the subject's ischemia-damaged tissue.

15

This invention provides the instant method, wherein the allogeneic stem cells are obtained from embryonic, fetal or cord blood sources.

20 This invention provides a method of stimulating angiogenesis in ischemia-damaged tissue in a subject comprising:

- (a) obtaining allogeneic stem cells;
- (b) recovering endothelial progenitor cells in the stem cells removed in step (a); and
- 25 (c) introducing the endothelial progenitor cells recovered in step (b) into the subject such that the endothelial progenitor cells stimulate angiogenesis in the subject's ischemia-damaged tissue.

This invention provides the instant method, wherein the allogeneic stem cells are obtained from embryonic, fetal or cord blood sources.

5 This invention also provides a method of improving myocardial function in a subject that has suffered a myocardial infarct comprising injecting G-CSF into the subject in order to mobilize endothelial progenitor cells.

10 This invention also provides a method of improving myocardial function in a subject that has suffered a myocardial infarct comprising injecting anti-CXCR4 antibody into the subject.

This invention also provides the instant method further  
15 comprising introducing endothelial progenitor cells into the subject.

This invention also provides the instant method further  
comprising introducing G-CSF into the subject in order to  
20 mobilize endothelial progenitor cells.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1. G-CSF Mobilizes Two Human Bone Marrow-Derived Populations Expressing VEGF Receptors: One With Characteristics Of Mature Endothelial Cells And A Second With Characteristics Of Embryonic Angioblasts.

A-D depicts four-parameter flow cytometric phenotype characterization of G-CSF mobilized bone marrow-derived cells removed by leukapheresis from a representative human donor adult (25). Only live cells were analyzed, as defined by 7-AAD staining. For each marker used, shaded areas represent background log fluorescence relative to isotype control antibody.

- A. Following immunoselection of mononuclear cells (25), >95% of live cells express CD34.
- 20 B. The CD34+CD117<sup>dim</sup> subset contains a population with phenotypic characteristics of mature, vascular endothelium.
- 25 C. The CD34+CD117<sup>bright</sup> subset contains a population expressing markers characteristic of primitive hemangioblasts arising during waves of murine and human embryogenesis.
- D. CD34+CD117<sup>bright</sup> cells co-expressing GATA-2 and GATA-3 also

express AC133, another marker which defines hematopoietic cells with angioblast potential.

**Figure 2. Bone Marrow-Derived Angioblasts (BA) Have Greater Proliferative Activity In Response To Both VEGF And Ischemic Serum Than Bone Marrow-Derived Endothelial Cells (BMEC).**

Depicted is the response of single-donor CD34-positive human cells sorted by a fluorescent GATA-2 mAb and cultured for 96 hours in RPMI with 20% normal rat serum, ischemic rat serum or 20 ng/ml VEGF. The numbers of CD117<sup>bright</sup>GATA-2<sup>pos</sup> and CD117<sup>dim</sup>GATA-2<sup>neg</sup> cells were quantitated by both [<sup>3</sup>H] thymidine uptake and by flow cytometry.

A. In comparison to culture in normal serum, the proliferative responses to either VEGF or ischemic serum were significantly higher for CD117<sup>bright</sup>GATA-2<sup>pos</sup> BA relative to CD117<sup>dim</sup>GATA-2<sup>neg</sup>BMEC from the same donor (both  $p < 0.01$ ).

B. The population expanded by culture with either VEGF or ischemic serum and characterized by multiparameter flow cytometric analysis as CD117<sup>bright</sup>GATA-2<sup>pos</sup> consisted of large blast cells, as demonstrated by high forward scatter (fsc).

C. The expanded population of CD117<sup>bright</sup>GATA-2<sup>pos</sup> cells did not demonstrate increased surface expression of mature

endothelial cell markers after culture with VEGF in comparison to culture with normal medium, indicating blast proliferation without differentiation.

5     **Figure 3. Highly Purified Human Bone Marrow-Derived CD34  
Cells Differentiate Into Endothelial Cells After *in*  
Vitro Culture.**

10     Culture of highly-purified CD34+ human cells for 7 days in  
endothelial growth medium results in outgrowth of cells with  
morphologic and characteristic features of mature endothelial  
cell monolayers. The majority of the monolayers (>90%)  
demonstrate:

- 15     A. Exuberant cobblestone pattern of cellular proliferation  
and growth;
- B. Uniform uptake of DiI-labeled acetylated LDL;
- 20     C. CD34 expression, as measured by immunofluorescence using  
a fluorescein-conjugated mAb;
- D. Factor VIII expression, as measured by immunoperoxidase  
using a biotin-conjugated mAb; and
- 25     E. Expression of eNOS, determined by *in situ* hybridization  
using a specific probe.

**Figure 4. *In vivo* migratory and proliferative characteristics**



of bone marrow- and peripheral vasculature-derived human cells after induction of myocardial ischemia.

- 5       A-C. Intravenous injection of  $2 \times 10^6$  DiI-labeled human CD34-enriched cells (>95% CD34 purity), CD34-negative cells (<5% CD34 purity), or saphenous vein endothelial cells (SVEC), into nude rats after coronary artery ligation and infarction. Each human cellular population caused a similar degree of infiltration in infarcted rat myocardium at 48 hours.
- 10
- D. A sham procedure, with no human cells found in the non-infarcted rat heart.
- 15       E. Measurement of human GATA-2 mRNA expression in the bone marrow and heart of infarcted rats receiving either CD34-positive cells (>95% CD34 purity), CD34-negative cells (<5% CD34 purity), normalized for total human RNA measured by GAPDH expression. GATA-2 mRNA in ischemic tissue is expressed as the fold increase above that present under the same experimental condition in the absence of ischemia. Bone marrow from ischemic rats receiving either CD34+ or CD34- cells contained similar levels of human GATA-2 mRNA, and showed a similar fold induction in GATA-2 mRNA expression after ischemia. In contrast, ischemic hearts of rats receiving CD34+ cells contained much higher levels of human GATA-2 mRNA than those receiving CD34- cells. Moreover, the degree of increase in GATA-2 mRNA expression after infarction was 2.6-fold higher for hearts infiltrated by CD34+ cells
- 20
- 25
- 30

compared with CD34- cells, indicating that GATA-2+ cells within the CD34+ fraction selectively traffic to ischemic myocardium.

- 5 F. Consecutive sections of a blood vessel within the infarct bed of a nude rat two weeks after injection of human CD34+ cells. The vessel incorporates human endothelial cells, as defined by co-expression of DiI, HLA class I as measured by immunofluorescence using a  
10 fluorescein-conjugated mAb, and factor VIII, as measured by immunoperoxidase using a biotin-conjugated mAb.

**Figure 5. Injection of G-CSF Mobilized Human CD34+ Cells Into Rats With Acute Infarction Improves Myocardial Function.**  
15

A-D compares the functional effects of injecting  $2 \times 10^6$  G-CSF mobilized human CD34+ (>95% purity) cells, CD34- (<5% purity) cells, peripheral saphenous vein cells, or saline, into  
20 infarcted rat myocardium.

A. Although left ventricular ejection fraction (LVEF) was severely depressed in each group of recipients after LAD ligation, only injection of G-CSF mobilized adult human  
25 CD34+ cells was accompanied by significant, and sustained, LVEF recovery ( $p < 0.001$ ). LVEF recovery was calculated as the mean % improvement between LVEF after LAD ligation and pre-infarct LVEF.

30 B. Similarly, although left ventricular end-systolic area

(LVAs) was markedly increased in each group of recipients after LAD ligation, only injection of G-CSF mobilized adult human CD34+ cells was accompanied by significant, and sustained, reduction in LVAs ( $p < 0.001$ ). Reduction in LVAs was calculated as the mean % improvement between LVAs after LAD ligation and pre-infarct LVAs.

C. Representative echocardiographic examples from each group are shown. At 48 hours after LAD ligation, diastolic function is severely compromised in each rat. At two weeks after injection, diastolic function is improved only in the rat receiving CD34+ cells. This effect persists at 15 weeks.

D. At 15 weeks post-infarction, rats injected with CD34+ cells demonstrated significantly less reduction in mean cardiac index relative to normal rats than each of the other groups ( $p < 0.001$ ).

**Figure 6. Injection Of G-CSF Mobilized Human CD34+ Cells Into Rats With Acute Infarction Induces Neo-Angiogenesis And Modifies The Process Of Myocardian Remodeling.**

A-D depicts infarcted rat myocardium at two weeks post-LAD ligation from representative experimental and control animals stained with either hematoxylin and eosin (A,B) or immunoperoxidase following binding of anti-factor VIII mAb (C,D). E,F depicts Mason trichrome stain of infarcted rat myocardium from representative control and experimental

animals at 15 weeks post-LAD ligation. G depicts between-group differences in % scar/normal left ventricular tissue at 15 weeks.

- 5     A.    Infarct zone of rat injected with human CD34+ cells demonstrates significant increase in microvasculature and cellularity of granulation tissue, numerous capillaries (arrowheads), feeding vessels (arrow), and decrease in matrix deposition and fibrosis (x200).
- 10     B.    In contrast, infarct zone of control rat injected with saline shows a myocardial scar composed of paucicellular, dense fibrous tissue (arrows) (x200).
- 15     C.    Ischemic myocardium of rat injected with human CD34+ cells demonstrates numerous factor VIII-positive interstitial angioblasts (arrows), and diffuse increase in factor VIII-positive capillaries (arrowheads) (x400).
- 20     D.    Ischemic myocardium of rat injected with saline does not contain factor VIII-positive angioblasts (arrows), and demonstrates only focal areas of granulation tissue with factor VIII positive vascularity (arrowheads) (x400).
- 25     E.    Trichrome stain of rat myocardium at 15 weeks post-infarction in rat injected with saline (x25). The collagen rich myocardial scar in the anterior wall of the left ventricle (ant.) stains blue and viable myocardium stains red. Focal islands of collagen
- 30     deposition (blue) are also present in the posterior wall

of the left ventricle (post). There is extensive loss of anterior wall myocardial mass, with collagen deposition and scar formation extending almost through the entire left ventricular wall thickness, causing aneurysmal dilatation and typical EKG abnormalities (persistent ST segment elevation).

F. In contrast, trichrome stain of rat myocardium at 15 weeks post-infarction in rat receiving highly purified CD34+ cells (x25) demonstrates significantly reduced infarct zone size together with increased mass of viable myocardium within the anterior wall (ant.) and normal EKG. Numerous vessels are evident at the junction of the infarct zone and viable myocardium. There is no focal collagen deposition in the left ventricular posterior wall (post).

G. Rats receiving CD34+ cells had a significant reduction in mean size of scar tissue relative to normal left ventricular myocardium compared with each of the other groups ( $p < 0.01$ ). Infarct size, involving both epicardial and endocardial regions, was measured with a planimeter digital image analyzer and expressed as a percentage of the total ventricular circumference at a given slice. For each animal, final infarct size was calculated as the average of 10-15 slices.

Figure 7. Human Adult Bone Marrow-Derived Endothelial Precursor Cells Infiltrate Ischemic Myocardium, Inducing Infarct Bed Neoangiogenesis And Preventing

**Collagen Deposition.**

- A. Four-parameter flow cytometric phenotypic characterization of G-CSF mobilized bone marrow-derived cells removed by leukopheresis from a representative human donor adult. Only live cells were analyzed, as defined by 7-AAD staining. For each marker used, shaded areas represent background log fluorescence relative to isotype control antibody. The CD34+CD117<sup>bright</sup> subset contains a population expressing markers characteristic of primitive haemangioblasts arising during waves of murine and human embryogenesis, but not markers of mature endothelium. These cells also express CXC chemokine receptors.
- B. DiI-labeled human CD34-enriched cells (>98% CD34 purity) injected intravenously into nude rats infiltrate rat myocardium after coronary artery ligation and infarction but not after sham operation at 48 hours.
- C. The myocardial infarct bed at two weeks post-LAD ligation from representative rats receiving  $2.0 \times 10^6$  G-CSF mobilized human bone marrow-derived cells at 2%, 40%, or 98% CD34+ purity, and stained with either Masson's trichrome or immunoperoxidase. The infarct zones of rats receiving either 2% or 40% pure CD34+ cells show myocardial scars composed of paucicellular, dense fibrous tissue stained blue (x400). In contrast, the infarct zone of the rat injected with 98% pure human CD34+ cells demonstrates significant increase in

microvasculature and cellularity of granulation tissue, numerous capillaries, and minimal matrix deposition and fibrosis (x400). Moreover, immunoperoxidase staining following binding of anti-factor VIII mAb shows that the infarct bed of the rat injected with 98% pure CD34+ cells demonstrates markedly increased numbers of factor VIII-positive capillaries, which are not seen in either of the other animals (x400).

**Figure 8. Migration Of Human Bone Marrow-Derived Endothelial Precursor Cells To The Site Of Infarction Is Dependent On Interactions Between CXCR1/2 And IL-8/Gro-Alpha Induced By Myocardial Ischemia.**

**A,B.** Time-dependent increase in rat myocardial IL-8 and Gro-alpha mRNA expression relative to GAPDH from rats undergoing LAD ligation.

**C.** IL-8, Gro-alpha, and GAPDH mRNA expression at baseline, 12 hours and 48 hours after LAD ligation from a representative animal.

**D.** Time-dependent measurement of rat IL-8/Gro-alpha protein in serum of rats undergoing LAD ligation. Migration of CD34+ human bone marrow-derived cells to ischemic rat myocardium is inhibited by mAbs against either rat IL-8 or the IL-8/Gro chemokine family receptors CXCR1 and CXCR2 (all  $p < 0.01$ ), but not against VEGF or its receptor Flk-1 (results are expressed as mean  $\pm$  sem of three separate experiments).

**Figure 9. CXC Chemokines Directly Induce Chemotaxis Of Bone Marrow-Derived Human CD34+ Cells To Rat Myocardium.**

5 A and B depict results of *in vitro* chemotaxis of 98% pure human CD34+ cells to various conditions using a 48-well chemotaxis chamber (Neuro Probe, MD). Chemotaxis is defined as the number of migrating cells per high power field (hpf) after examination of 10 hpf per condition tested.

10

A. IL-8 induces chemotaxis in a dose-dependent manner (results are expressed as mean  $\pm$  sem of three separate experiments).

15 B. Chemotaxis is increased in response to IL-8 and SDF-1 alpha/beta, but not VEGF or SCF.

C. Representative fluorescence microscopy demonstrating increased infiltration of intravenously-injected DiI-labeled human CD34+ cells (98% purity) into rat heart after intracardiac injection with IL-8 compared with saline injection.

20

D. Intracardiac injection of IL-8 at 1 mg/ml significantly increases *in vivo* chemotaxis of DiI-labeled human CD34+ cells (98% purity) into rat heart in comparison with injection of saline, VEGF or stem cell factor (SCF),  $p < 0.01$  (results are expressed as mean  $\pm$  sem of three separate experiments).

25

30



**Figure 10.      Blocking CXCR4/SDF-1 Interactions Redirects  
Intravenously Injected Human CD34+ Angioblasts  
From Bone Marrow To Ischemic Myocardium.**

- 5      A.    Depicted is the response of single-donor CD34-positive  
human cells cultured for 96 hours in RPMI with 20%  
normal rat serum, ischemic rat serum or 20 ng/ml VEGF.  
The numbers of CD117<sup>bright</sup>GATA-2<sup>pos</sup> cells were quantitated  
by both [<sup>3</sup>H] thymidine uptake and by flow cytometry.  
10      Ischemic serum induced a greater proliferative response  
of CD117<sup>bright</sup>GATA-2<sup>pos</sup> cells compared with each of the other  
conditions (both  $p < 0.01$ ).
- 15      B.    The proportion of human CD34+ cells in rat bone marrow  
2-14 days after intravenous injection is significantly  
increased after ischemia induced by LAD ligation  
(results are expressed as mean  $\pm$  sem of bone marrow  
studies in three animals at each time point).
- 20      C,D. Effects of mAbs against CXCR4, SDF-1 or anti-CD34 on  
trafficking of human CD34+ cells to rat bone marrow and  
myocardium following LAD ligation. Co-administration of  
anti-CXCR4 or anti-SDF-1 significantly reduced  
trafficking of 98% pure CD34+ cells to rat bone marrow  
25      at 48 hours and increased trafficking to ischemic  
myocardium (results are expressed as mean  $\pm$  sem of bone  
marrow and cardiac studies performed in three LAD-  
ligated animals at 48 hours after injection).

30      **Figure 11.      Redirected Trafficking Of Human CD34+**

**Angioblasts To The Site Of Infarction Prevents  
Remodeling And Improves Myocardial Function.**

- 5           A,B. The effects of human CD34<sup>+</sup> cells on reduction in LVAs  
          (A) and improvement in LVEF (B) after myocardial  
          infarction. Whereas injection of  $2.0 \times 10^6$  human cells  
          containing 98% CD34<sup>+</sup> purity significantly improved LVEF  
          and reduced LVAs (both  $p < 0.01$ ), injection of  $2.0 \times 10^6$   
10          human cells containing 2% and 40% CD34<sup>+</sup> purity did not  
          have any effect on these parameters in comparison to  
          animals receiving saline. However, co-administration of  
          anti-CXCR4 together with 40% pure CD34<sup>+</sup> cells  
          significantly improved LVEF and reduced LVAs (both  
           $p < 0.01$ ), to levels approaching use of cells with 98%  
15          purity.
- C.   Sections of rat hearts stained with Masson's trichrome  
          at 15 weeks after LAD ligation and injection of  $2.0 \times 10^6$   
          human cells containing 2%, 40%, or 98% CD34<sup>+</sup> purity.  
20          Hearts of rats receiving 2% and 40% pure CD34<sup>+</sup> cells had  
          greater loss of anterior wall mass, collagen deposition  
          (blue), and septal hypertrophy compared with hearts of  
          rats receiving 98% pure CD34<sup>+</sup> cells. Co-administration  
          of anti-CXCR4 mAb together with 40% pure CD34<sup>+</sup> cells  
25          increased left ventricular wall mass and reduced  
          collagen deposition.
- D.   Shows the mean proportion of scar/normal left  
          ventricular myocardium in rats receiving >98% pure CD34<sup>+</sup>  
30          cells or 40% pure CD34<sup>+</sup> cells together with anti-CXCR4

mAb is significantly reduced in comparison to rats receiving 2% and 40% pure CD34+ cells ( $p < 0.01$ ) (results are expressed as mean  $\pm$  sem of three separate experiments).

5

Figure 12. Culture of CD34+CD117<sup>bright</sup> angioblasts with serum from LAD-ligated rats increases surface expression of CCR1 and CCR2, while surface expression of CCR3 and CCR5 remains unchanged.

10

Figure 13. Infarcted myocardium demonstrate a time-dependent increase in mRNA expression of several CCR-binding chemokines.

15

Figure 14. Co-administration of blocking mAbs against MCP-1, MCP-3, and RANTES, or against eotaxin, reduced myocardial trafficking of human angioblasts by 40-60% relative to control antibodies ( $p < 0.01$ ).

20

Figure 15. Intracardiac injection of eotaxin into non-infarcted hearts induced 1.5-1.7 fold increase in CD34+ angioblast trafficking whereas injection of the growth factors VEGF and stem cell factor had no effect on chemotaxis despite increasing angioblast proliferation (not shown).

25

DETAILED DESCRIPTION OF THE INVENTION

As used herein, and unless stated otherwise, each of the following terms shall have the definition set forth below.

5

As used herein, "BMEC" is defined as bone marrow-derived endothelial cells.

10

As used herein, vasculogenesis is defined as the creation of new blood vessels from cells that are "pre-blood" cells such as bone marrow-derived endothelial cell precursors.

15

As used herein, mobilization is defined as inducing bone marrow-derived endothelial cell precursors to leave the bone marrow and enter the peripheral circulation. One of skill is aware that mobilized stem cells may be removed from the body by leukopheresis.

20

As used herein, ischemia is defined as inadequate blood supply (circulation) to a local area due to blockage of the blood vessels to the area.

25

As used herein, cytokine is defined as a factor that causes cells to grow or activate.

As used herein, chemokine is defined as a factor that causes cells to move to a different area within the body.

30

As used herein, ischemic heart disease is defined as any condition in which blood supply to the heart is decreased.

As used herein, "angiogenesis" is defined as the creation of blood vessels from pre-existing blood vessel cells.

5 As used herein, ischemic heart disease is defined as any condition in which blood supply to the heart is decreased.

As used herein, "VEGF" is defined as vascular endothelial growth factor. "VEGF-R" is defined as vascular endothelial growth factor receptor. "FGF" is defined as fibroblast growth factor. "IGF" is defined as Insulin-like growth factor. "SCF" is defined as stem cell factor. "G-CSF" is defined as granulocyte colony stimulating factor. "M-CSF" is defined as macrophage colony stimulating factor. "GM-CSF" is defined as granulocyte-macrophage colony stimulating factor. "MCP" is defined as monocyte chemoattractant protein.

10

15

As used herein, "CXC" chemokine refers to the structure of the chemokine. Each "C" represents a cysteine and "X" represents any amino acid.

20

As used herein, "CC" chemokine refers to the structure of the chemokine. Each "C" represents a cysteine.

As used herein, "recovered" means detecting and obtaining a cell based on the recoverable cell being a cell that binds a detectably labeled antibody directed against a specific marker on a cell including, but not limited to, CD117, GATA-2, GATA-3, and CD34.

25

As described herein, the chemokine administered to the

30

subject could be in the protein form or nucleic acid form.

This invention provides a method of stimulating vasculogenesis in ischemia-damaged tissue of a subject comprising:

- (a) removing stem cells from a location within the subject;
- (b) recovering endothelial progenitor cells from the stem cells removed in step (a); and
- (c) introducing the endothelial progenitor cells from step (b) into a different location within the subject such that the endothelial progenitor cells stimulate vasculogenesis in the subject's ischemia-damaged tissue.

In a further embodiment the endothelial progenitors are frozen for a period of time in between steps (b) and (c). In one embodiment the ischemia-damaged tissue is myocardium. In another embodiment the ischemia-damaged tissue is nervous system tissue.

In one embodiment the endothelial progenitors are expanded by contacting the endothelial progenitors with a growth factor subsequent to step (b), but before step (c). In a further embodiment the growth factor is a cytokine. In further embodiments the cytokine is VEGF, FGF, G-CSF, IGF, M-CSF, or GM-CSF. In another embodiment the growth factor is a chemokine. In a further embodiment the chemokine is Interleukin-8. In one embodiment the endothelial progenitors are separated from other stem cells before expansion. In a further embodiment the endothelial

progenitors are frozen for a period of time after expansion but before step (c).

5 In one embodiment step (a) occurs prior to the subject suffering ischemia-damaged tissue and wherein step (c) occurs after the subject has suffered ischemia-damaged tissue.

10 In one embodiment the stem cells are removed directly from the subject's bone marrow. In a further embodiment the stem cells are removed by aspiration from the subject's bone marrow. In one embodiment the stem cells are removed from the subject by a method comprising:

- 15 a) introducing a growth factor into the subject to mobilize the stem cells into the subject's blood; and
- b) subsequently removing a sample of blood containing stem cells from the subject.

20 In a further embodiment the growth factor is introduced subcutaneously, orally, intravenously or intramuscularly. In one embodiment the growth factor is a chemokine that induces mobilization. In a further embodiment the chemokine is Interleukin-8. In one embodiment the growth factor is a cytokine. In a further embodiment the cytokine is G-CSF,

25 M-CSF, or GM-CSF.

30 This invention also provides the instant method, wherein the endothelial progenitor cells are recovered based upon their expression of CD117.

This invention also provides the instant method, wherein the endothelial progenitor cells are recovered based upon their expression of a GATA-2 activated gene product. In one embodiment the gene product is selected from the following group: preproendothelin-1, big endothelin, endothelin-1.

In one embodiment the endothelial progenitors express GATA-2, and the endothelial progenitors are recovered as such by detection of intracellular GATA-2 expression or GATA-2 activity in those cells.

In one embodiment the subject has suffered or is suffering from one or more of the following: myocardial infarction, chronic heart failure, ischemic heart disease, coronary artery disease, diabetic heart disease, hemorrhagic stroke, thrombotic stroke, embolic stroke, limb ischemia or another disease in which tissue is rendered ischemic.

In one embodiment the endothelial progenitors are introduced into the subject by injection directly into the peripheral circulation, heart muscle, left ventricle, right ventricle, coronary artery, cerebro-spinal fluid, neural tissue, ischemic tissue or post-ischemic tissue.

In one embodiment the method further comprises administering to the subject one or more of the following: an inhibitor of Plasminogen Activator Inhibitor, Angiotensin Converting Enzyme Inhibitor or a beta blocker, wherein such administration occurs prior to, concomitant with, or following step (c).



40

This invention also provides a method of stimulating angiogenesis in peri-infarct tissue in a subject comprising:

- 5 (a) removing stem cells from a location within a subject;
- (b) recovering endothelial progenitor cells from the stem cells removed in step (a);
- (c) expanding the endothelial progenitor cells recovered in step (b) by contacting the  
10 progenitor cells with a growth factor; and
- (d) introducing the expanded endothelial progenitor cells from step (c) into a different location in the subject such that the endothelial progenitor cells stimulate  
15 angiogenesis in peri-infarct tissue in the subject.

This invention also provides a method of selectively increasing the trafficking of endothelial progenitor cells  
20 to ischemia-damaged tissue in a subject comprising:

- (a) administering endothelial progenitor cells to a subject; and
- (b) administering a chemokine to the subject so  
25 as to thereby attract the endothelial progenitor cells to the ischemia-damaged tissue.

In one embodiment the chemokine is administered to the subject prior to administering the endothelial progenitors.  
30 In an alternative embodiment the chemokine is administered

to the subject concurrently with the endothelial progenitors. In an alternative embodiment the chemokine is administered to the subject after administering the endothelial progenitors. In one embodiment the chemokine is a CXC chemokine. In a further embodiment the CXC chemokine is selected from the group consisting of Interleukin-8, Gro-Alpha, or Stromal-Derived Factor-1. In one embodiment the chemokine is a CC chemokine. In a further embodiment the CC chemokine is selected from the group consisting of RANTES, EOTAXIN, MCP-1, MCP-2, MCP-3, or MCP-4.

In one embodiment the chemokine is administered to the subject by injection into peripheral circulation, heart muscle, left ventricle, right ventricle, coronary arteries, cerebro-spinal fluid, neural tissue, ischemic tissue or post-ischemic tissue.

This invention also provides a method of increasing trafficking of endothelial progenitor cells to ischemia-damaged tissue in a subject comprising inhibiting any interaction between Stromal-Derived Factor-1 and CXCR4.

In one embodiment the interaction between Stromal-Derived Factor-1 (SDF-1) and CXCR4 is inhibited by administration of an anti-SDF-1 or an anti-CXCR4 monoclonal antibody to the subject. In one embodiment the instant method further comprises administering to the subject ACE inhibitor, AT-receptor blocker, or beta blocker. ng enzyme inhibitor, an AT<sub>1</sub>-receptor blocker, or a beta blocker.

5 This invention also provides a method of reducing trafficking of endothelial progenitor cells to bone marrow in a subject comprising inhibiting production of Stromal-Derived Factor-1 in the subject's bone marrow. In one embodiment the SDF-1 production is inhibited by administration of an anti-SDF-1 or anti-CXCR4 monoclonal antibody to the subject.

10 This invention also provides a method for treating a cancer in a subject comprising administering to the subject a monoclonal antibody directed against an epitope of a specific chemokine produced by proliferating cells associated with the cancer so as to reduce trafficking of  
15 endothelial progenitor cells to such proliferating cells and thereby treat the cancer in the subject.

This invention also provides a method for treating a cancer in a subject comprising administering to the subject a  
20 monoclonal antibody directed against an epitope of a specific receptor located on an endothelial progenitor cell, for a chemokine produced by proliferating cells associated with the cancer, so as to reduce trafficking of the endothelial progenitor cell to such proliferating cells  
25 and thereby treat the cancer in the subject.

This invention also provides a method for treating a tumor in a subject comprising administering to the subject an antagonist to a specific receptor on an endothelial  
30 progenitor cell so as to reduce the progenitor cell's

ability to induce vasculogenesis in the subject's tumor and thereby treat the tumor.

5 This invention also provides a method for treating a tumor in a subject comprising administering to the subject an antagonist to a specific receptor on an endothelial progenitor cell so as to reduce the progenitor cell's ability to induce angiogenesis in the subject's tumor and thereby treat the tumor.

10

This invention also provides a method for expressing a gene of interest in an endothelial progenitor cell or a mast progenitor cell which comprises inserting into the cell a vector comprising a promoter containing a GATA-2 motif and the gene of interest.

15

This invention also provides the instant method, wherein the vector is inserted into the cell by transfection.

20 This invention also provides the instant method, wherein the promoter is a preproendothelin-1 promoter.

This invention also provides the instant method, wherein the promoter is of mammalian origin.

25

This invention also provides the instant method, wherein the promoter is of human origin.

30 This invention provides a composition comprising an amount of a monoclonal antibody directed against an epitope of a

specific chemokine produced by a cancer effective to reduce trafficking of endothelial progenitor cells to the cancer, and a pharmaceutically acceptable carrier.

5 This invention provides a method of treating an abnormality in a subject wherein the abnormality is treated by the expression of a GATA-2 activated gene product in the subject comprising:

- 10 (a) removing stem cells from a location within the subject;
- (b) recovering endothelial progenitor cells from the stem cells removed in step (a);
- (c) recovering those endothelial progenitor cells recovered in step (b) that express  
15 GATA-2;
- (d) inducing the cells recovered in step (c) as expressing GATA-2 to express a GATA-2 activated gene product; and
- 20 (e) introducing the cells expressing a GATA-2 activated gene product from step (d) into a different location in the subject such as to treat the abnormality.

In one embodiment the abnormality is ischemia-damaged tissue. In one embodiment the gene product is  
25 proendothelin. In one embodiment the gene product is endothelin. In one embodiment the subject is a mammal. In a further embodiment the mammal is a human

This invention provides a method of treating an  
30 abnormality in a subject wherein the abnormality is treated

by the expression of a GATA-2 activated gene product in the subject comprising:

- (a) removing stem cells from a location within the subject;
- 5 (b) recovering mast progenitor cells from the stem cells removed in step (a);
- (c) recovering those mast progenitor cells recovered in step (b) that express GATA-2;
- (d) inducing the cells recovered in step (c) as  
10 expressing GATA-2 to express a GATA-2 activated gene product; and
- (e) introducing the cells expressing a GATA-2 activated gene product from step (d) into a different location in the subject such as to  
15 treat the abnormality

In one embodiment the abnormality is ischemia-damaged tissue. In one embodiment the gene product is proendothelin. In one embodiment the gene product is  
20 endothelin. In one embodiment the subject is a mammal. In a further embodiment the mammal is a human

This invention provides the a method of improving  
25 myocardial function in a subject that has suffered a myocardial infarct comprising:

- (a) removing stem cells from a location in the subject;
- (b) recovering cells that express CD117 from the  
30 stem cells; and

- (c) introducing the recovered cells into a different location in the subject such that the cells improve myocardial function in the subject.

5 In one embodiment the subject is a mammal. In a further embodiment the mammal is a human.

This invention also provides a method of stimulating vasculogenesis in ischemia-damaged tissue in a subject  
10 comprising:

- (a) obtaining allogeneic stem cells;
- (b) recovering endothelial progenitor cells from the stem cells removed in step (a); and
- (c) introducing the endothelial progenitor cells  
15 recovered in step (b) into the subject such that the endothelial progenitor cells stimulate vasculogenesis in the subject's ischemia-damaged tissue.

20 In alternative embodiments the allogeneic stem cells are removed from embryonic, fetal or cord blood sources.

This invention provides a method of stimulating angiogenesis in ischemia-damaged tissue in a subject comprising:

- (a) obtaining allogeneic stem cells;
- (b) recovering endothelial progenitor cells in the stem cells removed in step (a); and
- (c) introducing the endothelial progenitor cells  
25 recovered in step (b) into the subject such that the endothelial progenitor cells  
30

stimulate angiogenesis in the subject's  
ischemia-damaged tissue.

5 In alternative embodiments the allogeneic stem cells are  
removed from embryonic, fetal or cord blood sources.

10 This invention also provides a method of improving  
myocardial function in a subject that has suffered a  
myocardial infarct comprising injecting G-CSF into the  
subject in order to mobilize endothelial progenitor cells.

15 This invention also provides a method of improving  
myocardial function in a subject that has suffered a  
myocardial infarct comprising injecting anti-CXCR4 antibody  
into the subject. In one embodiment the method further  
comprises introducing endothelial progenitors into the  
subject. In one embodiment the method further comprises  
introducing G-CSF into the subject in order to mobilize  
endothelial progenitors.

20 This invention will be better understood by reference to  
the Experimental Details which follow, but those skilled  
in the art will readily appreciate that the specific  
experiments detailed are only illustrative of the invention  
25 as described more fully in the claims which follow  
thereafter.



EXPERIMENTAL DETAILSFirst Series of Experiments5      **EXPERIMENTAL PROCEDURES AND RESULTS**1.      **Mobilization and Identification of Bone Marrow-Derived  
Cells**

10      Following G-CSF mobilization, 60-80% of highly purified  
human CD34 cells (>90% positive) co-expressed the stem cell  
factor receptor CD117, figure 1a, of which 15-25% expressed  
CD117 brightly and 75-85% expressed CD117 dimly. By  
quadruple parameter analysis, two populations of CD34 cells  
15      were recovered which expressed VEGFR-2 (Flk-1), one  
accounting for 20-30% of CD117<sup>dim</sup> cells and expressing high  
levels of VEGFR-2, and a second accounting for 10-15% of  
CD117<sup>bright</sup> cells and expressing lower levels of VEGFR-2,  
figure 1b. The VEGFR-2 positive cells within the  
20      CD34+CD117<sup>dim</sup> population, but not those within the  
CD34+CD117<sup>bright</sup> subset, displayed phenotypic characteristics  
of mature, vascular endothelium, including high level  
expression of Tie-2, eNOS, vWF, E-selectin (CD62E), and  
ICAM (CD54). In contrast, as shown in figure 1c, the  
25      VEGFR-2 positive cells within the CD34+CD117<sup>bright</sup> subset, but  
not those within the CD34+CD117<sup>dim</sup> subset, expressed markers  
characteristic of primitive hemangioblasts arising during  
waves of murine and human embryogenesis, including GATA-2,  
GATA-3, and low levels of Tie-2. Moreover, CD117<sup>bright</sup> cells  
30      which co-expressed GATA-2 and GATA-3 were also strongly

AC133 positive, another marker which has recently been suggested to define a hematopoietic population with angioblast potential (2), figure 1d. However, since AC133 expression was also detected on a subset of CD117<sup>dim</sup> cells which was negative for GATA-2 and GATA-3, we conclude that identification of an embryonic bone-marrow derived angioblast (BA) phenotype requires concomitant expression of GATA-2, GATA-3, and CD117<sup>bright</sup> in addition to AC133. Thus, G-CSF treatment mobilizes into the peripheral circulation a prominent population of mature, bone marrow-derived endothelial cells (BMEC), and a smaller bone marrow-derived population with phenotypic characteristics of embryonic angioblasts (BA).

## 2. Expansion of Bone Marrow-Derived Cells

Since the frequency of circulating endothelial cell precursors in animal models has been shown to be increased by either VEGF (27) or regional ischemia (10-13), we next compared the proliferative responses of BA and BMEC to VEGF and to factors in ischemic serum (28). As shown in figure 2a, following culture for 96 hours with either VEGF or ischemic serum, CD117<sup>bright</sup>GATA-2<sup>pos</sup> BA demonstrated significantly higher proliferative responses relative to CD117<sup>dim</sup>GATA-2<sup>neg</sup> BMEC from the same donor. For VEGF, BA showed 2.9-fold increase in proliferation above baseline compared with 1.2-fold increase for BMEC,  $p < 0.01$ , while for ischemic serum from Lew rats with myocardial infarction BA showed 4.3-fold increase in proliferation above normal serum compared with 1.7-fold increase for BMEC,  $p < 0.01$ .

Culture with either VEGF or ischemic serum greatly expanded the BA population of large blast cells, figure 2b, which continued to express immature markers, including GATA-2, GATA-3, and CD117<sup>bright</sup>, but not markers of mature endothelial cells, figure 2c, indicating blast proliferation without differentiation. Following culture of CD34-positive monolayers on fibronectin in endothelial growth medium for 7 days (29), an exuberant cobblestone pattern of proliferation was seen, figure 3a, with the majority of the adherent monolayers (>95%) having features characteristic of endothelial cells, figure 3b-e, including uniform uptake of acetylated LDL, and co-expression of CD34, factor VIII, and eNOS. Since the BMEC population had low proliferative responses to VEGF or cytokines in ischemic serum, the origin of the exuberant endothelial cell outgrowth in culture is most likely the BA population defined by surface expression for GATA-2, GATA-3, and CD117<sup>bright</sup>.

### 3. In vivo Migration of Bone Marrow-Derived CD34+ Cells to Sites of Regional Ischemia

Next we compared the *in vivo* migratory and proliferative characteristics of bone marrow- and peripheral vasculature-derived human cells after induction of regional ischemia. As shown in figure 4a-c, intravenous injection of  $2 \times 10^6$  DiI-labeled human CD34-positive cells (>95% CD34 purity), CD34-negative cells (<5% CD34 purity), or saphenous vein endothelial cells (SVEC), into nude rats after coronary artery ligation and infarction resulted in similar degree of infiltration in rat myocardium at 48 hours (30) The

trafficking was specifically directed to the infarct area since few DiI-labeled cells were detected in unaffected areas of hearts with regional infarcts, not shown, and neither G-CSF mobilized CD34+ cells nor mature human endothelial cells infiltrated normal myocardium, figure 4d. Although similar numbers of CD34+ and CD34- cells migrated to ischemic myocardium, the proportional increase in human GATA-2 mRNA expression in ischemic myocardium relative to normal myocardium (31) was 2.6-fold greater following injection of highly CD34-enriched cells compared with CD34- cells ( $p < 0.001$ ), figure 4e. Moreover, blood vessels which incorporated human endothelial cells, as defined by co-expression of DiI, HLA class I, and factor VII, could be detected two weeks after injection of human CD34+ cells, but not after injection of CD34- cells or SVEc, figure 4f. Together, these results indicate that adult bone marrow-derived human CD34+ cells contain a population which selectively responds to *in vivo* signals from sites of regional ischemia with augmented migration, localization, and endothelial differentiation.

#### 4. Effects of Injection of G-CSF mobilized Human CD34+ Cells into Infarcted Rat Myocardium

We next compared the functional effects of injecting G-CSF mobilized human CD34+ (>95%) cells, CD34- (<5%) cells, peripheral saphenous vein cells, or saline, into infarcted rat myocardium. After LAD ligation, left ventricular function was severely depressed in each group of recipients, with left ventricular ejection fraction (LVEF)

being reduced by means of 25-43% and left ventricular end-systolic area being increased by means of 44-90%, figure 5 a and b. Remarkably, within two weeks of injecting G-CSF mobilized adult human CD34+ cells, LVEF recovered by a mean of  $22 \pm 6\%$  ( $p < 0.001$ ), figure 5a. This effect was long-lived, and increased by the end of follow-up, 15 weeks, to  $34 \pm 4\%$ . In contrast, injection of G-CSF mobilized human CD34- cells, saphenous vein endothelial cells, or saline, had no effect on LVEF. In a parallel fashion, injection of G-CSF mobilized human CD34+ cells reduced left ventricular end-systolic area by a mean of  $26 \pm 8\%$  by 2 weeks and  $37 \pm 6\%$  by 15 weeks, whereas none of the other recipient groups demonstrated such effect ( $p < 0.001$ ), figure 5b. Representative echocardiographic examples for each group are shown in figure 5c. Moreover, at 15 weeks post-infarction mean cardiac index in rats injected with CD34+ cells was only reduced by  $26 \pm 8\%$  relative to normal rats, whereas mean cardiac index for each of the other groups was reduced by 48-59% ( $p < 0.001$ ), figure 5d.

Histologic examination at two weeks post-infarction (33) revealed that injection of CD34+ cells was accompanied by significant increase in microvasculature and cellularity of granulation tissue, and decrease in matrix deposition and fibrosis within the infarct zone in comparison to controls, figure 6 a and b. Moreover, ischemic myocardium of rats injected with human CD34+ cells contained significantly greater numbers of factor VIII-positive interstitial angioblasts and capillaries in comparison to ischemic myocardium of control rats, figure 6 c and d.

Quantitation of capillary numbers demonstrated a significant increase in neo-angiogenesis within the infarct zone of rats who received CD34+ cells (mean number of factor VIII-positive capillaries per high power field  $92 \pm 5$  vs  $51 \pm 4$  in saline controls,  $p < 0.01$ ), but not within normal myocardium ( $36 \pm 2$  vs  $37 \pm 3$  capillaries per high power field). No increase in capillary numbers were observed in ischemic rat myocardium infiltrated with CD34-cells or SVEC. At 15 weeks post-infarction, rats receiving highly purified CD34+ cells demonstrated significantly reduced infarct zone sizes together with increased mass of viable myocardium within the anterior free wall compared to each of the other groups, figure 6e and f. Numerous vessels were evident at the junction of the infarct zone and viable myocardium in tissues infiltrated with CD34+ cells. Whereas collagen deposition and scar formation extended almost through the entire left ventricular wall thickness in controls, with aneurysmal dilatation and typical EKG abnormalities, the infarct scar extended only to 20-50% of the left ventricular wall thickness in rats receiving CD34+ cells. Moreover, pathological collagen deposition in the non-infarct zone was markedly reduced in rats receiving CD34+ cells. Overall, the mean proportion of scar/normal left ventricular myocardium was 13% in rats receiving CD34+ cells compared with 36-45% for each of the other groups ( $p < 0.01$ ), figure 6g.

#### DISCUSSION

The experiments described above demonstrate that neo-

angiogenesis of the infarct bed by human bone marrow-derived endothelial cell precursors prevents scar development, maintains viable myocardium, and improves ventricular function in a rodent model of myocardial ischemia. Following infarction, the viable myocardial tissue bordering the infarct zone undergoes a significant degree of hypertrophy (5,34-35). Although neoangiogenesis within the infarcted tissue appears to be an integral component of the remodeling process (36,37), under normal circumstances the capillary network cannot keep pace with tissue growth and is unable to support the greater demands of the hypertrophied, but viable, myocardium which subsequently undergoes apoptosis due to inadequate oxygenation and nutrient supply. The development of neoangiogenesis within the myocardial infarct scar appears to require activation of latent collagenase and other proteinases following plasminogen activation by urokinase-type plasminogen activator (u-PA) expressed on infiltrating leukocytes (38). The importance of bone marrow-derived endothelial precursors in this process has been demonstrated in u-PA  $\alpha$  mice where transplantation of bone marrow from cogenic wild-type strains restored defective myocardial revascularization post-infarction (38). Since u-PA mRNA transcription and proteolytic activity in human mononuclear cells and tumor cell lines is significantly increased by the colony stimulating factors G-CSF, M-CSF, and GM-CSF (39-41), this provides a rationale for *in vivo* or *ex vivo* use of these cytokines to mobilize and differentiate large numbers of human adult bone marrow-derived angioblasts for therapeutic revascularization of

the infarct zone.

Cell surface and RNA expression of the transcription factor GATA-2 appears to selectively identify human adult bone marrow-derived angioblasts capable of responding to signals from ischemic sties by proliferating and migrating to the infarct zone, and subsequently participating in the process of neo-angiogenesis. Of particular interest, GATA-2 is a co-factor for endothelial cell transcription of preproendothelin-1 (ppET-1) (42), the precursor molecule of the potent vasoconstrictor and hypertrophic autocrine peptide ET-1. Since ppET-1 transcription is also increased by angiotensin II (43), produced as a result of activation of the renin-angiotensin neurohormonal axis following myocardial infarction, the angioblasts infiltrating the infarct bed may be secreting high levels of ET-1 due to the synergistic actions of angiotensin II surface receptor signalling and GATA-2 transactivation. The observation that newly-formed vessels within the infarct scar have thicker walls, lower vasodilator responses to stronger vasoactive substances than vessels within normal myocardium (44) are consistent with effects of increased autocrine ET-1 activity, and support the possibility that neo-angiogenic vasculature is derived from infiltrating GATA-2 positive angioblasts.

Together, the results of the above-described experiments indicate that injection of G-CSF mobilized adult human CD34+ cells with phenotypic and functional properties of embryonic hemangioblasts can stimulate neo-angiogenesis in



the infarct vascular bed, thus reducing collagen deposition and scar formation in myocardial infarction. Although the degree of reduction in myocardial remodeling as a result of neoangiogenesis was striking, further augmentation in myocardial function might be achieved by combining infusion of human angioblasts with ACE inhibition or AT<sub>1</sub>-receptor blockade to reduce angiotensin II-dependent cardiac fibroblast proliferation, collagen secretion, and plasminogen activator-inhibitor (PAI) production (45, 46). The use of cytokine-mobilized autologous human bone-marrow angioblasts for revascularization of myocardial infarct tissue, in conjunction with currently used therapies (47-49), offers the potential to significantly reduce morbidity and mortality associated with left ventricular remodeling post-myocardial infarction.

#### Second Series of Experiments

#### **METHODS**

20

##### **1. Purification of Cytokine-Mobilized Human CD34+ Cells**

25

30

Single-donor leukopheresis products were removed from humans treated with recombinant G-CSF 10 mg/kg (Amgen, CA) sc daily for four days. Mononuclear cells were separated by Ficoll-Hypaque, and highly-purified CD34+ cells (>98% positive) were removed using magnetic beads coated with anti-CD34 monoclonal antibody (mAb) (Miltenyi Biotech Ltd, CA). Purified CD34 cells were stained with fluorescein-conjugated mAbs against CD34, CD117, VEGFR-2, Tie-2, GATA-

2, GATA-3, AC133, vWF, eNOS, CD54, CD62E, CXCR1, CXCR2, CXCR4, and analyzed by four-parameter fluorescence using FACScan (Becton Dickinson, CA).

5        2.     Proliferative Studies of Human Endothelial Progenitors

Single-donor CD34-positive cells were cultured for 96 hours in RPMI with either 20% normal rat serum, ischemic rat  
10     serum or 20 ng/ml VEGF, then pulsed with [<sup>3</sup>H] thymidine (Amersham Life Science Inc, IL, USA) (1 mCi/well) and uptake was measured in an LK Betaplate liquid scintillation counter (Wallace, Inc., Gaithersburg, MD). The proportion of CD117<sup>bright</sup>GATA-2<sup>pos</sup> cells after 96 hours of culture in each  
15     condition was also quantitated by flow cytometry.

3.     Chemotaxis of Human Bone Marrow-Derived Endothelial Progenitors

20     Highly-purified CD34+ cells (>98% positive) were plated in 48-well chemotaxis chambers fitted with membranes (8 mm pores) (Neuro Probe, MD). After incubation for 2 hours at 37°, chambers were inverted and cells were cultured for 3 hours in medium containing IL-8 at 0.2, 1.0 and 5.0 mg/ml, SDF-1 alpha/beta 1.0 mg/ml, VEGF and SCF. The membranes  
25     were fixed with methanol and stained with Leukostat (Fischer Scientific, Ill). Chemotaxis was calculated by counting migrating cells in 10 high-power fields.

30     4.     Animals, Surgical procedures, Injection of Human

Cells, and Quantitation of Cellular Migration into  
Tissues

Rowett (rnu/rnu) athymic nude rats (Harlan Sprague Dawley,  
5 Indianapolis, Indiana) were used in studies approved by the  
"Columbia University Institute for Animal Care and Use  
Committee". After anesthesia, a left thoracotomy was  
performed, the pericardium was opened, and the left  
anterior descending (LAD) coronary artery was ligated.  
10 Sham-operated rats had a similar surgical procedure without  
having a suture placed around the coronary artery. 48  
hours after LAD ligation  $2.0 \times 10^6$  DiI-labeled human CD34+  
cells (>95%, 40%, <2% purity) removed from a single donor  
after G-CSF mobilization were injected into the tail vein  
15 in the presence or absence of mAbs with known inhibitory  
activity against CXCR1, CXCR2, CXCR4, CD34, rat IL-8  
(ImmunoLaboratories, Japan) and rat SDF-1<sup>®</sup> & D Systems,  
MN), or isotype control antibodies. Control animals  
received saline after LAD ligation. Each group consisted  
20 of 6-10 rats. Quantitation of myocardial infiltration  
after injection of human cells was performed by assessment  
of DiI fluorescence in hearts from rats sacrificed 2 days  
after injection (expressed as number of DiI-positive cells  
per high power field, minimum 5 fields examined per  
25 sample). Quantitation of rat bone marrow infiltration by  
human cells was performed in 12 rats at baseline, days 2,  
7, and 14 by flow cytometric and RT-PCR analysis of the  
proportion of HLA class I-positive cells relative to the  
total rat bone marrow population.

## 5. Analyses of Myocardial Function

Echocardiographic studies were performed at baseline, 48 hours after LAD ligation, and at 2, 6 and 15 weeks after injection of cells or saline, using a high frequency liner array transducer (SONOS 5500, Hewlett Packard, Andover, MA). 2D images were removed at mid-papillary and apical levels. End-diastolic (EDV) and end-systolic (ESV) left ventricular volumes were removed by bi-plane area-length method, and % left ventricular ejection fraction (LVEF) was calculated as  $[(EDV-ESV)/EDV] \times 100$ . Left ventricular area at the end of systole (LVAs) was measured by echocardiography at the level of the mitral valve. LVEF recovery and reduction in LVAs were calculated as the mean improvement between the respective values for each at different time points after LAD ligation relative to pre-infarct values.

## 6. Histology and Immunohistochemistry

Histologic studies were performed on explanted rat hearts at 2 and 15 weeks after injection of human cells or saline. Following excision, left ventricles from each experimental animal were sliced at 10-15 transverse sections from apex to base. Representative sections were put into formalin for histological examination, stained freshly with anti-factor VIII mAb using immunoperoxidase technique to quantitate capillary density, or stained with Masson trichrome and mounted. The lengths of the infarcted surfaces, involving both epicardial and endocardial

60

regions, were measured with a planimeter digital image analyzer and expressed as a percentage of the total ventricular circumference. Final infarct size was calculated as the average of all slices from each heart.

5

#### 7. Measurement of Rat CXC Chemokine mRNA and Protein Expression

Poly(A)+ mRNA was extracted by standard methods from the hearts of 3 normal and 12 LAD-ligated rats. RT-PCR was used to quantify myocardial expression of rat IL-8 and Gro-alpha mRNA at baseline and at 6, 12, 24 and 48 hours after LAD ligation after normalizing for total rat RNA as measured by GAPDH expression. After priming with oligo (dT) 15-mer and random hexamers, and reverse transcribed with Monoley murine lymphotropic virus reverse transcriptase (Invitrogen, Carlsbad, CA, USA), cDNA was amplified in the polymerase chain reaction (PCR) using Taq polymerase (Invitrogen, Carlsbad, CA, USA), radiolabeled dideoxy-nucleotide ([ $\alpha^{32}$ P]-ddATP: 3,000 Ci/mmol, Amersham, Arlington Heights, IL), and primers for rat IL-8, Gro-alpha and GAPDH (Fisher Genosys, CA). Primer pairs (sense/antisense) for rat IL-8, Gro-alpha AND GAPDH were, gaagatagattgcaccgatg (SEQ ID NO:1) /catagcctctcacatttc (SEQ ID NO:2), ggcgccgtccgccaatgagctgcgc (SEQ ID NO:3)/cttggggacacccttcagcatcttttgg (SEQ ID NO:4), and ctctacccacggcaagttcaa (SEQ ID NO:5)/gggatgaccttgcccacagc (SEQ ID NO:6), respectively. The labeled samples were loaded into 2% agarose gels, separated by electrophoresis, and exposed for radiography for 6 h at -70°. Serum levels

30

of rat IL-8/Gro-alpha were measured at baseline and at 6, 12, 24 and 48 hours after LAD ligation in four rats by a commercial ELISA using polyclonal antibodies against the rat IL-8/Gro homologue CINC (ImmunoLaboratories, Japan).  
5 The amount of protein in each serum sample was calculated according to a standard curve of optical density (OD) values constructed for known levels of rat IL-8/Gro-alpha protein.

## 10 EXPERIMENTAL PROCEDURES AND RESULTS

### 1. Selective Trafficking of Endothelial Precursors

Following immunoselection of G-CSF mobilized human CD34  
15 cells to >98% purity, 60-80% co-expressed the stem cell factor receptor CD117. By quadruple parameter analysis, figure 7a, 10-15% of CD117<sup>bright</sup> cells were found to express a phenotype characteristic of embryonic angioblasts, with low level surface expression of VEGFR-2 and Tie-2, as well as  
20 the transcription factors GATA-2 and GATA-3, and AC133, recently shown to identify endothelial precursors (79). These cells did not express markers of mature endothelial cells such as vWF, eNOS and E-selectin, but were positive for the CXC chemokine receptors 1, 2, and 4. Intravenous  
25 injection of  $2 \times 10^6$  DiI-labeled human CD34+ cells (>98%, 40%, and 2% purity) into LAD-ligated Rowett nude rats was accompanied at 48 hours by dense infiltration of rat myocardium, figure 7b. The trafficking of these cells was specifically directed to the infarct area since few DiI-  
30 labeled cells were detected in unaffected areas of hearts

with regional infarcts, not shown, and DiI-labeled cells did not infiltrate myocardium from sham-operated rats, figure 7b. By two weeks post-injection, rats receiving >98% pure human CD34+ cells demonstrated increased infarct bed microvasculature and reduced matrix deposition and fibrosis, figure 7c. The number of factor VIII-positive capillaries per high power field was over three-fold higher in the infarct bed of rats receiving  $2 \times 10^6$  cells containing >98% pure CD34+ purity than in the analogous region in rats receiving  $2 \times 10^6$  cells containing either 2% or 40% CD34+ purity,  $p < 0.01$ , figure 7c. Moreover, the majority of these capillaries were of human origin since they expressed HLA class I molecules (not shown). Thus, although various populations of human bone marrow-derived cells migrate to the infarct bed, vasculogenesis appears to require selective trafficking of a critical number of endothelial precursors.

## 2. Effects of Ischemia on CXC Chemokine Production by Infarcted Myocardium

Since human leukocyte chemotaxis and tissue infiltration is regulated by interactions between specific chemokines and CXC cell surface receptors, we next investigated the effects of ischemia on CXC chemokine production by infarcted rat myocardium. As shown in figure 8a-c, infarcted myocardium demonstrated a time-dependent increase in mRNA expression of the CXCR1/2-binding ELR-positive chemokines IL-8 and Gro- $\alpha$ , with maximal expression at 6-12 hours after LAD ligation. In comparison to non-

infarcted myocardium, tissues after LAD ligation expressed 7.2-7.5 fold higher mRNA levels of these ELR-positive pro-angiogenic chemokines after normalizing for total mRNA content ( $p < 0.001$ ). Moreover, serum IL-8 levels increased by 8-10 fold within 6-12 hours after LAD ligation ( $p < 0.001$ ), and remained elevated at 48 hours, figure 8d. Co-administration of blocking mAbs against either IL-8 and Gro-alpha, or against the surface receptors for these pro-angiogenic chemokines, CXCR1 or CXCR2, reduced myocardial trafficking of human angioblasts by 40-60% relative to control antibodies ( $p < 0.01$ ), figure 8e.

### 3. Chemotactic Responses of Human Bone Marrow-Derived CD34+ Angioblasts to Chemokines.

In subsequent experiments we directly measured *in vitro* and *in vivo* chemotactic responses of human bone marrow-derived CD34+ angioblasts to IL-8. As shown in figure 9a, *in vitro* chemotaxis of human CD34+ cells was induced by IL-8 in a dose-dependent manner, with concentrations between 0.2-5  $\mu$ /ml. The ELR- chemokine SDF-1, produced constitutively by bone marrow stromal cells, induced a similar degree of chemotaxis of CD34+ cells at concentrations similar to IL-8, figure 9b. In contrast, chemotaxis was not induced by the growth factors VEGF or stem cell factor (SCF). Moreover, intracardiac injection of IL-8 at 1  $\mu$ g/ml into non-infarcted hearts induced *in vivo* chemotaxis of CD34+ cells, figure 9c, whereas neither VEGF nor SCF, used as controls, had any chemotactic effect *in vivo*, figure 9d. Together, these results indicate that increased tissue



expression of ELR-positive chemokines augments vasculogenesis *in vivo* by inducing chemotaxis of bone marrow-derived endothelial precursor cells to sites of tissue ischemia.

5

#### 4. Interruption of CXCR4/SDF-1 Interactions to Redirect Trafficking of Human CD34-Positive Cells from Bone Marrow to Myocardium.

10 In addition to augmenting trafficking of intravenously injected human CD34+ angioblasts to damaged myocardium, ischemic serum from LAD-ligated rats caused rapid expansion of the circulating CD34+CD117<sup>bright</sup> angioblast population and concomitantly increased trafficking of these cells to the  
15 bone marrow. As shown in figure 10a, culture for 2 days with either VEGF or ischemic serum increased proliferation of CD34+CD117<sup>bright</sup> angioblasts by 2.8 and 4.3 fold, respectively ( $p < 0.01$ ). Moreover, as shown in figure 10b, bone marrow from ischemic rats after LAD ligation contained  
20 5-8 fold higher levels of human CD34+CD117<sup>bright</sup> angioblasts compared with bone marrow from normal rats 2-14 days after intravenous injection of  $2 \times 10^6$  human CD34-positive cells (>95% purity), ( $p < 0.001$ ). Since SDF-1 is constitutively expressed by bone marrow stromal cells and preferentially  
25 promotes bone marrow migration of circulating CD34+ cells which are actively cycling (80), we investigated whether the increased homing of human CD34+CD117<sup>bright</sup> angioblasts to ischemic rat bone marrow was due to heightened SDF-1/CXCR4 interactions. As shown in figure 10c, co-administration of  
30 mAbs against either human CXCR4 or rat SDF-1 significantly

inhibited migration of intravenously administered CD34+ human angioblasts to ischemic rat bone marrow by compared with anti-CD34 control antibody (both  $p < 0.001$ ). Moreover, co-administration of mAbs against either human CXCR4 or rat SDF-1 increased trafficking of CD34+ human angioblasts to ischemic rat myocardium by a mean of 24% and 17%, respectively (both  $p < 0.001$ ), figure 10d. By two weeks, the myocardial infarct bed of rats receiving human CD34+ cells in conjunction with anti-CXCR4 mAb demonstrated >3-fold increase in microvascularity compared with those receiving CD34+ cells in conjunction with isotype control antibody. These results indicate that although intravenously injected CD34+ angioblasts traffick to infarcted myocardium and induce vasculogenesis in response to augmented production of ELR+ chemokines, the efficiency of this process is significantly reduced by concomitant angioblast migration to the bone marrow in response to SDF-1. Interruption of CXCR4/SDF-1 interactions redirects trafficking of the expanded, cycling population of human CD34-positive cells from bone marrow to myocardium after infarction, increasing infarct bed neoangiogenesis.

#### 5. Improvement in Myocardial Function

Although left ventricular function was severely depressed after LAD ligation, injection of >98% pure CD34+ cells was associated with significant recovery in left ventricular size and function within two weeks, and these effects persisted for the entire 15 week period of follow-up, figure 11 a and b. In rats receiving >98% pure CD34+

cells, left ventricular end-systolic area decreased by a mean of  $37 \pm 6\%$  by 15 weeks compared to immediately post-infarction, figure 11a, and left ventricular ejection fraction (LVEF) recovered by a mean of  $34 \pm 4\%$  by 15 weeks (p<0.001), figure 11b (p<0.001). Improvement in these parameters depended on the number of CD34+ cells injected, since intravenous injection of  $2 \times 10^6$  G-CSF mobilized human cells containing 2% or 40% CD34+ purity did not significantly improve myocardial function despite similar degrees of trafficking to ischemic myocardium, figures 11 a and b. However, co-administration of anti-CXCR4 mAb together with G-CSF mobilized human bone marrow-derived cells containing 40% CD34+ purity significantly improved LVEF recovery and reduced LVAs, to levels seen with >98% CD34+ purity. By trichrome stain, significant differences in left ventricular mass and collagen deposition were observed between the groups, figure 11c. In rats receiving  $2 \times 10^6$  human cells containing 2% CD34 purity, the left ventricular anterior wall was completely replaced by fibrous tissue and marked compensatory septal hypertrophy was present. Similar changes were seen in hearts of rats receiving  $2 \times 10^6$  human cells containing 40% CD34 purity. In contrast, in hearts of rats receiving  $2 \times 10^6$  human cells containing 98% CD34 purity significantly greater anterior wall mass was maintained, with normal septal size and minimal collagen deposition. Of particular interest, hearts of rats receiving  $2 \times 10^6$  human cells containing 40% purity together with anti-CXCR4 mAb demonstrated similar increase in anterior myocardial wall mass, decrease in septal hypertrophy, and reduction in collagen deposition.

Overall, the mean proportion of fibrous scar/normal left ventricular myocardium was 13% and 21%, respectively, in rats receiving >98% pure CD34+ cells or 40% pure CD34+ cells together with anti-CXCR4 mAb, compared with 36-45% for rats receiving 2% and 40% pure CD34+ cells ( $p < 0.01$ ), figure 11d. Thus, augmentation of infarct bed vasculogenesis by increasing selective trafficking of a critical number of endothelial precursors leads to further prevention of the remodeling process, salvage of viable myocardium, and improvement in cardiac function.

#### DISCUSSION

This study demonstrates that ELR+ chemokines produced by ischemic tissues regulate the development of compensatory vasculogenesis at ischemic sites by producing a chemoattractant gradient for bone marrow-derived endothelial cell precursors. Although both the ELR+ CXC chemokine IL-8 and the ELR- CXC chemokine SDF-1 demonstrate similar effects on chemotaxis of CD34+ endothelial precursors, as well as on mature endothelium (73), when expressed at different extravascular sites they impart opposing biological effects on directional egress of endothelial progenitors, and consequently on tissue neovascularization. By understanding these interactions we were able to manipulate and augment the chemotactic properties of a specific subset of human bone marrow-derived CD34+ cells in order to increase myocardial trafficking, induce infarct bed vasculogenesis, reduce post-ischemic ventricular remodeling, and improve

myocardial function.

Since migration of bone marrow-derived progenitors through basement membrane is dependent on secretion of proteolytic enzymes such as metalloproteinase-9 (MMP-9, Gelatinase B) (81), intracardiac metalloproteinase activity may be a critical determinant of angioblast extravasation from the circulation and transendothelial migration into the infarct zone. IL-8 induces rapid release (within 20 minutes) of the latent form of MMP-9 from intracellular storage granules in neutrophils (82-83), and increases serum MMP-9 levels by up to 1,000-fold following intravenous administration *in vivo* in non-human primates (84). Since IL-8 significantly increases MMP-9 expression in bone marrow progenitors (81), and neutralizing antibodies against MCP-9 prevent mobilization of these cells (85), the results of our study suggest that angioblast infiltration and subsequent infarct bed vasculogenesis may result from IL-8-dependent increases in MMP-9 secretion.

20

Activation of latent MMP-9 and concomitant development of neoangiogenesis within murine myocardial infarct scar tissue has been shown to depend on urokinase-type plasminogen activator (u-PA) co-expressed by bone marrow progenitors infiltrating the infarct bed (81). Transcription and proteolytic activity of u-PA in human cells is significantly increased by G-CSF and other colony stimulating factors (86-88). Since IL-8-induced chemotaxis and progenitor mobilization require the presence of additional signals delivered through functional G-CSF

30

receptors (89), it is possible that increased u-PA activity is required for IL-8 mediated trafficking of angioblasts to sites of ischemia. This would explain the limited extent of infarct bed neoangiogenesis observed normally after myocardial infarction (62,63) despite high levels of IL-8 production, and provides a rationale for *in vivo* or *ex vivo* administration of colony stimulating factors to mobilize and differentiate human bone marrow-derived angioblasts for use in therapeutic revascularization of ischemic tissues.

10

Constitutive production of the CXC chemokine SDF-1 by bone marrow stromal cells appears to be essential for bone marrow homing and engraftment of haematopoietic progenitors (76-78). In addition, expression of SDF-1 in non-haematopoietic tissues plays a role in the developing vascular system since SDF-1  $-/-$  mice have defects in both vascularization of the gastrointestinal tract (50) and ventricular septum formation (90). Since bone marrow-derived endothelial precursors express CXCR4 (80) and demonstrate chemotactic responses to SDF-1, as shown here, induced expression of SDF-1 at non-haematopoietic sites during embryogenesis or following tissue injury may be an important element in the process of tissue neovascularization (91). Our ability to redirect trafficking of human bone marrow-derived angioblasts to sites of tissue ischemia by interruption of CXCR4/SDF-1 interactions argues strongly that SDF-1 is a biologically active chemotactic factor for human endothelial precursors, and that it may have pro-angiogenic activity if expressed

30

at non-haematopoietic sites. Future studies will address whether increased expression and localization of SDF-1 and other chemokines at the sites of tissue ischemia might be synergistic with ELR+ CXC chemokines in augmenting vasculogenesis. Together, the results of this study indicate that CXC chemokines, including IL-8, Gro-alpha, and SDF-1, play a central role in regulating human bone marrow-dependent vasculogenesis, and that manipulation of interactions between these chemokines and their receptors on autologous human bone marrow-derived angioblasts can enhance the potential efficacy of therapeutic vasculogenesis following tissue ischemia.

### Third Series of Experiments

#### EXPERIMENTAL PROCEDURES AND RESULTS

##### 1. Myocardial Ischemia Induces Production Of CC Chemokines And Increases Human CD34+ Angioblast Expression Of CC Chemokine Receptors

Since human mononuclear cell chemotaxis and tissue infiltration is regulated by interactions between cell surface receptors with specific chemokine ligands, the effects of ischemia on angioblast CC chemokine receptor expression and on kinetics of CC chemokine production by infarcted rat myocardium were investigated. As shown in figure 12, culture of CD34+CD117<sup>bright</sup> angioblasts with serum from LAD-ligated rats increased surface expression of CCR1

and CCR2, while surface expression of CCR3 and CCR5 remained unchanged.

As shown in figure 13, infarcted myocardium demonstrated a time-dependent increase in mRNA expression of several CCR-binding chemokines. Infarcted myocardium was found to express over 8-fold higher levels of the CCR2-binding CC chemokine MCP-1, and 3-3.5-fold higher mRNA levels of MCP-3 and RANTES, as well as the CCR3-binding chemokine eotaxin, after normalizing for total mRNA content (all  $p < 0.001$ ). This pattern of gene expression appeared to be relatively specific since every infarcted tissue studied demonstrated increased expression of these CC chemokines and none demonstrated induced expression of the CCR5-binding CC chemokines MIP-1 alpha or MIP-1beta.

## 2. Trafficking Of Human CD34+ Angioblasts To Ischemic Myocardium Is Regulated By Induced Expression Of CC And CXC Chemokines

Next investigated was whether human angioblast trafficking to ischemic myocardium was related to the induced expression of the CC chemokines identified above. Co-administration of blocking mAbs against MCP-1, MCP-3, and RANTES, or against eotaxin, reduced myocardial trafficking of human angioblasts by 40-60% relative to control antibodies ( $p < 0.01$ ), figure 14. To prove that CC chemokines mediate angioblast chemotaxis to ischemic myocardium, we measured *in vivo* angioblast chemotaxis in response to eotaxin. As shown in figure 15, intracardiac



injection of eotaxin into non-infarcted hearts induced 1.5-1.7 fold increase in CD34+ angioblast trafficking whereas injection of the growth factors VEGF and stem cell factor had no effect on chemotaxis despite increasing angioblast proliferation (not shown).

#### Fourth Series of Experiments

**Determination of Myocyte Size.** Myocyte size was measured in normal rat hearts and in the infarct zone, peri-infarct rim and distal areas of infarct tissue sections stained by trichrome. The transverse and longitudinal diameters (mm) of 100-200 myocytes in each of 10-15 high-powered fields were measured at 400x using Image-Pro Plus software.

#### **Measurement Of Myocyte Apoptosis By DNA End-Labeling of Paraffin Tissue Sections.**

For in situ detection of apoptosis at the single cell level we used the TUNEL method of DNA end-labeling mediated by dexynucleotidyl transferase (TdT) (Boehringer Mannheim, Mannheim, Germany). Rat myocardial tissue sections were removed from LAD-ligated rats at two weeks after injection of either saline or CD34+ human cells, and from healthy rats as negative controls. Briefly, tissues were deparaffinized, digested with Proteinase K, and incubated with TdT and fluorescein-labeled dUTP in a humid atmosphere for 60 minutes at 37°C. After incubation for 30 minutes with an antibody specific for fluorescein conjugated alkaline phosphatase the TUNEL stain was visualized in which nuclei with DNA fragmentation stained blue.

# **1. Neoangiogenesis Protects Hypertrophied Myocardium Against Apoptosis.**

The mechanism by which induction of neo-angiogenesis resulted in improved cardiac function was investigated. Results showed that two weeks after LAD ligation the myocytes in the peri-infarct rim of saline controls had distorted appearance, irregular shape, and similar diameter to myocytes from rats without infarction (0.020 mm +/- 0.002 vs 0.019 mm +/- 0.001). In contrast, the myocytes at the peri-infarct rim of rats who received CD34+ cells had regular, oval shape, and were significantly larger than myocytes from control rats (diameter 0.036 mm +/- 0.004 vs 0.019 mm +/- 0.001,  $p < 0.01$ ). By concomitant staining for the myocyte-specific marker desmin and DNA end-labeling, 6-fold lower numbers of apoptotic myocytes were detected in infarcted left ventricles of rats injected with CD34+ cells compared with saline controls (apoptotic index  $1.2 \pm 0.6$  vs  $7.1 \pm 0.7$ ,  $p < 0.01$ ). These differences were particularly evident within the peri-infarct rim, where the small, irregularly-shaped myocytes in the saline-treated controls had the highest index of apoptotic nuclei. In addition, whereas apoptotic myocytes extended throughout 75-80% of the left ventricular wall in saline controls, apoptotic myocytes were only detectable for up to 20-25% of the left ventricle distal to the infarct zone in rats injected with CD34+ cells. Together, these results indicate that the infarct zone vasculogenesis and peri-infarct angiogenesis induced by injection of CD34+ cells prevented an eccentrically-extending pro-apoptotic process evident in saline controls, enabling survival of hypertrophied

myocytes within the peri-infarct zone and improving myocardial function.

## 2. Early Neoangiogenesis Prevents Late Myocardial Remodeling.

The last series of experiments showed the degree of peri-infarct rim myocyte apoptosis at two weeks in control and experimental groups (saline vs CD34+ cells) compared with progressive myocardial remodeling over the ensuing four months. Despite similar initial reductions in LVEF and increases in LVAS, by two weeks the mean proportion of collagenous deposition or scar tissue/normal left ventricular myocardium, as defined by Masson's trichrome stain, was 3% in rats receiving CD34+ cells compared with 12% for those receiving saline. By 15 weeks post-infarction, the mean proportion of scar/normal left ventricular myocardium was 13% in rats receiving CD34+ cells compared with 36-45% for each of the other groups studied (saline, CD34-, SVEC) ( $p < 0.01$ ). Rats receiving CD34+ cells demonstrated significantly increased mass of viable myocardium within the anterior free wall which comprised myocytes exclusively of rat origin, expressing rat but not human MHC molecules, confirming intrinsic myocyte salvage rather than myocyte regeneration from human stem cell precursors. Whereas collagen deposition and scar formation extended almost through the entire left ventricular wall thickness in controls, with aneurysmal dilatation and typical EKG abnormalities, the infarct scar extended only to 20-50% of the left ventricular wall thickness in rats receiving CD34+ cells. Moreover,

pathological collagen deposition in the non-infarct zone was markedly reduced in rats receiving CD34+ cells. Together, these results indicate that the reduction in peri-infarct myocyte apoptosis observed at two weeks resulted in prolonged survival of hypertrophied, but viable, myocytes and prevented myocardial replacement with collagen and fibrous tissue by 15 weeks.

#### DISCUSSION

The observation that proliferating capillaries at the peri-infarct rim and between myocytes were of rat origin shows that in addition to vasculogenesis human angioblasts or other co-administered bone-marrow derived elements may be a rich source of pro-angiogenic factors, enabling additional induction of angiogenesis from pre-existing vasculature.

REFERENCES

1. Mahon NG, et al. Heart 1999;81:478-82.
- 5 2. Pfeffer JM, Pfeffer MA, Fletcher PJ, Braunwald E. Am J Physiol 1991; 260:H1406-14.
3. White HD, et al. Circulation 1987; 76:44-51.
- 10 4. Colucci WS. Am J Cardiol 1997;80(11A):15L-25L.
5. Ravichandran LV and Puvanakrishnan R. Biochem Intl 1991;24:405-414.
- 15 6. Agocha A, Lee H-W, Eghali-Webb M. J Mol Cell Cardiol 1997;29:2233-2244.
7. Hochman JS and Choo H. Circulation 1987;75:299-306.
- 20 8. White HD, et al. Circulation 1994;89:61-67.
9. Nidorf SM, Siu SC, Galambos G, Weyman AE, Picard MH. J Am Coll Cardiol 1992;20:307-313.
- 25 10. Asahara T, et al. Science 1997;275:964-967.
11. Takahashi T, et al. Nat Med 1999;5:434-438.
12. Asahara T, et al. Circ Res 1999;85:221-228.

13. Kalka C, et al. Proc Natl Acad Sci USA 2000;97:3422-3427.
14. Rafii S, et al. Blood 1994;84:10-19.
15. Shi Q, et al. Blood 1998;92:362-367.
16. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. J Clin Invest 2000;105:71-77.
17. Tavian M, et al. Blood 1996;87:67-72.
18. Jaffredo T, Gautier R, Eichmann A, Dieterlen-Lievre F. Development 1998;125:4575-4583.
19. Kennedy M, et al.. Nature 1997;386:488-493.
20. Choi K, Kennedy M, Kazarov A, Papadimitriou, Keller G. Development 1998;125:725-732.
21. Elefanty AG, Robb L, Birner R, Begley CG. Blood 1997;90:1435-1447.
22. Labastie M-C, Cortes F, Romeo P-H, Dulac C, Peault B. Blood 1998;92:3624-3635.
23. Tsai FY, et al. Nature 1994;371:221-225.
24. Ogawa M, et al. Blood 1999;93:1168-1177.

25. Peichev M, et al. Blood. 2000;95:952-8.
26. Asahara T, et al. EMBO J 1999; 18:3964-3972.
- 5 27. Karam R, Healy BP, Wicker P. Circulation 1990;81:238-246.
28. Olivetti G, Capasso JM, Meggs LG, Sonnenblick EH, Anversa P. Circ Res 1991;68:856-869.
- 10 29. Braunwald E and Pfeffer MA. Am J Cardiol 1991;68(supplD):1-6D.
30. Nelissen-Vrancken H, Debets J, Snoeckx L, Daemen M, Smits J. Circulation 1996;93:349-355.
- 15 31. Kalkman EAJ, et al. Cardiovasc Res 1996.
32. Heymans S, et al. Nat Med 1999;5:1135-1142.
- 20 33. Hart PH, et al. Blood 1991;77:841-848.
34. Stacey KJ, et al. Mol Cell Biol 1995;15:3430-3441.
- 25 35. Pei X-H, et al. Clin Exp Metastasis 1998;16:551-558.
36. McEwan PE, Gray GA, Sherry L, Webb DJ, Kenyon CJ. Circulation 1998;98:2765-2773.
- 30 37. Kawano H, et al. Circulation 2000;101:1130-1137.

38. Chua BH, Chua CC, Diglio CA, Siu BB. *Biochim Biophys Acta* 1993;1178:201-206.
39. Ito H, et al. *J Clin Invest* 1993;92:398-403.
- 5 40. Rossi AP, Sacchetto A, Cesari M, Pessina AC. *Cardiovasc Res* 1999;43:300-307.
41. Dorfman DM, Wilson DB, Bruns GA, Orkin SH. *J Biol Chem* 1992; 267:1279-85.
- 10 42. Tasaka K, Kitazumi K. *Gen Pharmacol* 1994;25:1059-69.
43. Kalkman EAJ, van Haren P, Saxena PR, Schoemaker RG. *J Mol Cell Cardiol* 1997;29:1487-1497.
- 15 44. Pfeffer MA, et al. *N Engl J Med* 1992;327:669-677.
45. The SOLVD investigators. *N Engl J Med* 1991;325:293-302.
- 20 46. Pitt B, et al. *Lancet* 1997;349:747-752.
47. Strieter, RM. et al. Interleukin-8: a corneal factor that induces neovascularization. *Am. J. Pathol.* 141,1279-1284 (1992).
- 25 48. Koch, AE. et al. Interleukin-8 (IL-8) as a macrophage-derived mediator of angiogenesis. *Science*, 258:1798-1801 (1992).
- 30



49. Strieter, RM, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. *J. Biol. Chem.* 270, 27348-27357 (1995).
50. Tachibana, K. et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. *Nature* 393, 591-594 (1998).
51. Rafii S, et al. Isolation and characterization of human bone marrow microvascular endothelial cells: hematopoietic progenitor cell adhesion. *Blood* 84, 10-19 (1994).
52. Shi, Q. et al. Evidence for circulating bone marrow-derived endothelial cells. *Blood* 92, 362-367 (1998).
53. Lin, Y., Weisdorf, D. J., Solovey, A., Hebbel, R. P. Origins of circulating endothelial cells and endothelial outgrowth from blood. *J. Clin. Invest.* 105, 71-77 (2000).
54. Kennedy, M. et al. A common precursor for primitive erythropoiesis and definitive haematopoiesis. *Nature* 386, 488-493 (1997).

55. Choi, K., Kennedy, M., Kazarov, A., Papadimitriou, Keller, G. A common precursor for hematopoietic and endothelial cells. *Development* 125, 725-732 (1998).
- 5 56. Elefanty, A. G., Robb, L., Birner, R., Begley, C. G. Hematopoietic-specific genes are not induced during in vitro differentiation of scl-null embryonic stem cells. *Blood* 90, 1435-1447 (1997).
- 10 57. Labastie, M. C., Cortes, F., Romeo, P. H., Dulac, C., Peault, B. Molecular identity of hematopoietic precursor cells emerging in the human embryo. *Blood* 92, 3624-3635 (1998).
- 15 58. Folkman, J. Therapeutic angiogenesis in ischemic limbs. *Circulation* 97, 108-110 (1998).
59. Asahara, T. et al. Isolation of putative progenitor cells for endothelial angiogenesis. *Science* 275, 964-20 967 (1997).
60. Takahashi, T. et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. *Nat. Med.* 5, 25 434-438 (1999).
61. Kalka, C. et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. *Proc. Natl. Acad. Sci. USA* 97, 3422-3427 (2000). 30

- 5 62. Nelissen-Vrancken, H. J., Debets, J. J., Snoeckx L. H., Daemen, M. J., Smits, J.F. Time-related normalization of maximal coronary flow in isolated perfused hearts of rats with myocardial infarction. *Circulation* 93, (2) 349-355 (1996).
- 10 63. Kalkman, E. A. et al. Determinants of coronary reserve in rats subjected to coronary artery ligation or aortic banding. *Cardiovasc. Res.* 32, (6) 1088-1095 (1996).
- 15 64. Colucci, W. S. Molecular and cellular mechanisms of myocardial failure. *Am. J. Cardiol.* 80(11A), 15L-25L (1997).
- 20 65. Ravichandran, L. V. and Puvanakrishnan, R. In vivo labeling studies on the biosynthesis and degradation of collagen in experimental myocardial infarction. *Biochem. Intl.* 24, 405-414 (1991).
- 25 66. Agocha, A., Lee, H. W., Eghali-Webb, M. Hypoxia regulates basal and induced DNA synthesis and collagen type I production in human cardiac fibroblasts: effects of TGF-beta, thyroid hormone, angiotensin II and basic fibroblast growth factor. *J. Mol. Cell. Cardiol.* 29, 2233-2244 (1997).
- 30 67. Mahon, N. G. et al. Hospital mortality of acute

myocardial infarction in the thrombolytic era. *Heart* 81, 478-482 (1999).

- 5 68. Pfeffer, J. M., Pfeffer, M. A., Fletcher, P. J., Braunwald, E. Progressive ventricular remodeling in rat with myocardial infarction. *Am. J. Physiol.* 260, H1406-414 (1991).
- 10 69. White, H. D. et al. Left ventricular end systolic volume as the major determinant of survival after recovery from myocardial infarction. *Circulation* 76, 44-51 (1987).
- 15 70. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nat. Med.* 1:27 (1995).
- 20 71. Murdoch C, Monk PN, Finn A. Cxc chemokine receptor expression on human endothelial cells. *Cytokine* 11,704-12 (1999).
72. Angiolillo, AL, et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. *J Exp Med* 182,155-62 (1995).
- 25 73. Feil C, Augustin HG. Endothelial cells differentially express functional CXC-chemokine receptor-4 (CXCR-4/fusin) under the control of autocrine activity and exogenous cytokines. *Biochem Biophys Res Commun* 247, 38-45 (1998).

74. Tavian, M. et al. Aorta-associated CD34 hematopoietic cells in the early human embryo. *Blood* 87, 67-72 (1996).
- 5 75. Jaffredo, T., Gautier, R., Eichmann, A., Dieterlen-Lievre, F. Intraaortic hemopoietic cells are derived from endothelial cells during ontogeny. *Development* 125, 4575-4583 (1998).
- 10 76. Mohle R, Bautz F, Rafii S, Moore MA, Brugger W, Kanz L. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. *Blood* 91, 4523-30 (1998).
- 15 77. Imai, K. et al. Selective secretion of chemoattractants for haemopoietic progenitor cells by bone marrow endothelial cells: a possible role in homing of haemopoietic progenitor cells to bone marrow. *Br J Haematol* 106, 905-11 (1999).
- 20 78. Peled, A. et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. *Science* 283, 845-88 (1999).
- 25 79. Peichev M, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. *Blood* 95, 952-8 (2000).
- 30

80. Voermans C, Gerritsen WR, von dem Borne AE, van der Schoot CE. Increased migration of cord blood-derived CD34+ cells, as compared to bone marrow and mobilized peripheral blood CD34+ cells across uncoated or fibronectin-coated filters. *Exp. Hematol.* 27, 1806-14 (2000).
81. Janowska-Wieczorek, A. et al. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34+ cells and their transmigration through reconstituted basement membrane. *Blood* 93, 3379-3390 (1999).
82. Masure, S., Proost, P., Van Damme, J., Opdenakker, MD. Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. *Eur. J. Biochem.* 198, 391-398 (1991).
83. Pugin, J. et al. Human neutrophils secrete gelatinase B *in vitro* and *in vivo* in response to endotoxin and proinflammatory mediators. *Am. J. Respir. Cell. Mol. Biol.* 20, 458-464 (1999).
84. Pruijt JF, et al. Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9). *Proc Natl Acad Sci U S A.* 96, 10863-10868 (1999).
85. Heymans, S. et al. Inhibition of plasminogen

activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. *Nat. Med.* 5, 1135-1142 (1999).

5

86. Hart, P. H. et al. Activation of human monocytes by granulocyte-macrophage colony-stimulating factor: increased urokinase-type plasminogen activator activity. *Blood* 77, 841-848 (1991).

10

87. Stacey, K. J., Fowles, L. F., Colman, M. S., Ostrowski, M. C., Hume, D. A. Regulation of urokinase-type plasminogen activator gene transcription by macrophage colony-stimulating factor. *Mol. Cell. Biol.* 15, 3430-3441 (1995).

15

88. Pei, X. H. et al. G-CSF increases secretion of urokinase-type plasminogen activator by human lung cancer cells. *Clin. Exp. Metastasis* 16, 551-558 (1998).

20

89. Semerad, CL, et al. A role for G-CSF receptor signalling in the regulation of hematopoietic cell function but not lineage commitment or differentiation. *Immunity* 11, 153-161 (1999).

25

90. Nagasawa, T, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXCL12 chemokine PBSF/SDF-1. *Nature* 382, 635-638 (1996).

30

91. Rempel SA, Dudas S, Ge S, Gutierrez JA. Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma, *ClinCancerRes* 6, 102-11 (2000).
- 5



What is claimed:

1. A method of stimulating vasculogenesis in ischemia-damaged tissue of a subject comprising:
  - 5 (a) removing stem cells from a location within the subject;
  - (b) recovering endothelial progenitor cells from the stem cells removed in step (a); and
  - 10 (c) introducing the endothelial progenitor cells from step (b) into a different location within the subject such that the endothelial progenitor cells stimulate vasculogenesis in the subject's ischemia-damaged tissue.
- 15 2. The method of claim 1, wherein subsequent to step (b), but before step (c), the endothelial progenitor cells are expanded by contacting them with a growth factor.
- 20 3. The method of claim 2, wherein the growth factor is a cytokine.
4. The method of claim 3, wherein the cytokine is VEGF, FGF, G-CSF, IGF, M-CSF, or GM-CSF.
- 25 5. The method of claim 2, wherein the growth factor is a chemokine.
6. The method of claim 5, wherein the chemokine is Interleukin-8.

7. The method of claim 2, wherein the endothelial progenitor cells are separated from other stem cells before expansion.
- 5 8. The method of claim 1, wherein the ischemia-damaged tissue is myocardium.
9. The method of claim 1, wherein the ischemia-damaged tissue is nervous system tissue.
- 10 10. The method of claim 1, wherein the stem cells are removed from the subject's bone marrow.
11. The method of claim 10, wherein the removal of the stem cells from the bone marrow is effected by aspiration from the subject's bone marrow.
- 15 12. The method of claim 1, wherein the removal of the stem cells from the subject is effected by a method comprising:
- 20 (a) introducing a growth factor into the subject to mobilize the stem cells into the subject's blood; and
- (b) removing a sample of blood containing the stem cells from the subject.
- 25 13. The method of claim 12, wherein the growth factor is introduced into the subject subcutaneously, orally, intravenously or intramuscularly.

14. The method of claim 12, wherein the growth factor is a chemokine that induces mobilization.
15. The method of claim 14, wherein the chemokine is Interleukin-8.
16. The method of claim 12, wherein the growth factor is a cytokine.
17. The method of claim 16, wherein the cytokine is G-CSF, M-CSF, or GM-CSF.
18. The method of claim 1, wherein the endothelial progenitor cells are recovered based upon their expression of CD117.
19. The method of claim 1, wherein the endothelial progenitor cells are recovered based upon their expression of a GATA-2 activated gene product.
20. The method of claim 1, wherein the endothelial progenitor cells are recovered based upon their expression of one or more of CD34, VEGF-R, Tie-2, GATA-3 or AC133.
21. The method of claim 1, wherein the subject has suffered or is suffering from one or more of the following: myocardial infarction, chronic heart failure, ischemic heart disease, coronary artery disease, diabetic heart disease, hemorrhagic stroke,

thrombotic stroke, embolic stroke, limb ischemia, or another disease in which tissue is rendered ischemic.

5           22. The method of claim 1 or 2, wherein step (a) occurs prior to the subject suffering ischemia-damaged tissue and wherein step (c) occurs after the subject has suffered ischemia-damaged tissue.

10           23. The method of claim 1, wherein the endothelial progenitor cells are frozen for a period of time between steps (b) and (c).

15           24. The method of claim 2, wherein the endothelial progenitor cells are frozen for a period of time after being expanded but before step (c) is performed.

20           25. The method of claim 1, wherein the endothelial progenitor cells are introduced into the subject by injection directly into the peripheral circulation, heart muscle, left ventricle, right ventricle, coronary artery, cerebro-spinal fluid, neural tissue, ischemic tissue, or post-ischemic tissue.

25           26. The method of claim 1, further comprising administering to the subject one or more of the following: an inhibitor of Plasminogen Activator Inhibitor, Angiotensin Converting Enzyme Inhibitor or a beta blocker, wherein such administration occurs prior to, concomitant with, or following step (c).

27. A method of stimulating angiogenesis in peri-infarct tissue in a subject comprising:

- (a) removing stem cells from a location within the subject;
- 5 (b) recovering endothelial progenitor cells from the stem cells removed in step (a);
- (c) expanding the endothelial progenitor cells recovered in step (b) by contacting the progenitor cells with a growth factor; and
- 10 (d) introducing the expanded endothelial progenitor cells from step (c) into a different location in the subject such that the endothelial progenitor cells stimulate angiogenesis in peri-infarct tissue in the subject.

15

28. A method of selectively increasing the trafficking of endothelial progenitor cells to ischemia-damaged tissue in a subject comprising:

- (a) administering endothelial progenitor cells to the subject; and
- 20 (b) administering a chemokine to the subject so as to thereby attract the endothelial progenitor cells to the ischemia-damaged tissue.

25 29. The method of claim 28, wherein the chemokine is administered to the subject prior to administering the endothelial progenitor cells.

30 30. The method of claim 28, wherein the chemokine is administered to the subject concurrently with the

endothelial progenitor cells.

5 31. The method of claim 28, wherein the chemokine is administered to the subject after administering the endothelial progenitor cells.

32. The method of claim 28, wherein the chemokine is a CXC chemokine.

10 33. The method of claim 32, wherein the CXC chemokine is selected from the group consisting of Interleukin-8, Gro-Alpha, or Stromal-Derived Factor-1.

15 34. The method of claim 28, wherein the chemokine is a CC chemokine.

35. The method of claim 34, wherein the CC chemokine is selected from the group consisting of RANTES, EOTAXIN, MCP-1, MCP-2, MCP-3, or MCP-4.

20 36. The method of claim 28, wherein the chemokine is administered to the subject by injection into the subject's peripheral circulation, heart muscle, left ventricle, right ventricle, coronary arteries, cerebro-spinal fluid, neural tissue, ischemic tissue, or post-ischemic tissue.

25

30 37. A method of increasing trafficking of endothelial progenitor cells to ischemia-damaged tissue in a subject comprising inhibiting any interaction between

Stromal-Derived Factor-1 and CXCR4.

- 5 38. The method of claim 37, wherein interaction between Stromal-Derived Factor-1 (SDF-1) and CXCR4 is inhibited by administration of an anti-SDF-1 or an anti-CXCR4 monoclonal antibody to the subject.
- 10 39. The method of claim 38, further comprising administering to the subject an angiotensin converting enzyme inhibitor, an AT<sub>1</sub>-receptor blocker, or a beta blocker.
- 15 40. A method of reducing trafficking of endothelial progenitor cells to bone marrow in a subject comprising inhibiting production of Stromal-Derived Factor-1 in the subject's bone marrow.
- 20 41. The method of claim 40, wherein SDF-1 production is inhibited by administration of an anti-SDF-1 or anti-CXCR4 monoclonal antibody to the subject.
- 25 42. A method for treating a cancer in a subject comprising administering to the subject a monoclonal antibody directed against an epitope of a specific chemokine produced by proliferating cells associated with the cancer so as to reduce trafficking of endothelial progenitor cells to such proliferating cells and thereby treat the cancer in the subject.
- 30 43. A method for treating a cancer in a subject comprising

administering to the subject a monoclonal antibody directed against an epitope of a specific receptor located on an endothelial progenitor cell, for a chemokine produced by proliferating cells associated with the cancer, so as to reduce trafficking of the endothelial progenitor cell to such proliferating cells and thereby treat the cancer in the subject.

44. A method for treating a tumor in a subject comprising administering to the subject an antagonist to a specific receptor on an endothelial progenitor cell so as to reduce the progenitor cell's ability to induce vasculogenesis in the subject's tumor and thereby treat the tumor.

45. A method for treating a tumor in a subject comprising administering to the subject an antagonist to a specific receptor on an endothelial progenitor cell so as to reduce the progenitor cell's ability to induce angiogenesis in the subject's tumor and thereby treat the tumor.

46. The method of claim 44 or 45, wherein the receptor is a CD117 receptor.

47. A method for expressing a gene of interest in an endothelial progenitor cell or a mast progenitor cell which comprises inserting into the cell a vector comprising a promoter containing a GATA-2 motif and the gene of interest.



48. The method of claim 47, wherein the vector is inserted into the cell by transfection.
- 5 49. The method of claim 47, wherein the promoter is a preproendothelin-1 promoter.
50. The method of claim 49, wherein the promoter is of mammalian origin.
- 10 51. The method of claim 50, wherein the promoter is of human origin.
- 15 52. A composition comprising an amount of a monoclonal antibody directed against an epitope of a specific chemokine produced by a cancer effective to reduce trafficking of endothelial progenitor cells to the cancer, and a pharmaceutically acceptable carrier.
- 20 53. A method of treating an abnormality in a subject wherein the abnormality is treated by the expression of a GATA-2 activated gene product in the subject comprising:
- 25 (a) removing stem cells from a location within the subject;
- (b) recovering endothelial progenitor cells from the stem cells removed in step (a);
- (c) recovering those endothelial progenitor cells recovered in step (b) that express GATA-2;
- 30 (d) inducing the cells recovered in step (c) as

97

expressing GATA-2 to express a GATA-2 activated gene product; and

- (e) introducing the cells expressing a GATA-2 activated gene product from step (d) into a different location in the subject such as to treat the abnormality.

54. A method of treating an abnormality in a subject wherein the abnormality is treated by the expression of a GATA-2 activated gene product in the subject comprising:

- (a) removing stem cells from a location within the subject;
- (b) recovering mast progenitor cells from the stem cells removed in step (a);
- (c) recovering those mast progenitor cells recovered in step (b) that express GATA-2;
- (d) inducing the cells recovered in step (c) as expressing GATA-2 to express a GATA-2 activated gene product; and
- (e) introducing the cells expressing a GATA-2 activated gene product from step (d) into a different location in the subject such as to treat the abnormality

55. The method of claims 53 or 54, wherein the abnormality is ischemia-damaged tissue.

56. The method of claims 53 or 54, wherein the gene product is proendothelin.

57. The method of claims 53 or 54, wherein the gene product is endothelin.

5 58. A method of improving myocardial function in a subject that has suffered a myocardial infarct comprising:

- 10 (a) removing stem cells from a location in the subject;
- (b) recovering cells that express CD117 from the stem cells; and
- (c) introducing the recovered cells into a different location in the subject such that the cells improve myocardial function in the subject.

15 59. The method of any of claims 42, 43, 44, and 45, wherein the subject is of mammalian origin.

60. The method of claim 59, wherein the mammal is of human origin.

20 61. A method of stimulating vasculogenesis in ischemia-damaged tissue in a subject comprising:

- 25 (a) obtaining allogeneic stem cells;
- (b) recovering endothelial progenitor cells from the stem cells removed in step (a); and
- (c) introducing the endothelial progenitor cells recovered in step (b) into the subject such that the endothelial progenitor cells stimulate vasculogenesis in the subject's ischemia-damaged tissue.
- 30

62. The method of claim 61, wherein the allogeneic stem cells are obtained from embryonic, fetal or cord blood sources.

5       63. A method of stimulating angiogenesis in ischemia-damaged tissue in a subject comprising:  
      (a) obtaining allogeneic stem cells;  
      (b) recovering endothelial progenitor cells in the stem cells removed in step (a); and  
10       (c) introducing the endothelial progenitor cells recovered in step (b) into the subject such that the endothelial progenitor cells stimulate angiogenesis in the subject's ischemia-damaged tissue.

15

64. The method of claim 63, wherein the allogeneic stem cells are obtained from embryonic, fetal or cord blood sources.


20       65. A method of improving myocardial function in a subject that has suffered a myocardial infarct comprising injecting G-CSF into the subject in order to mobilize endothelial progenitor cells.

25       66. A method of improving myocardial function in a subject that has suffered a myocardial infarct comprising injecting anti-CXCR4 antibody into the subject.


30       67. The method of claim 66 further comprising introducing endothelial progenitor cells into the subject.

68. The method of claim 67 further comprising introducing G-CSF into the subject in order to mobilize endothelial progenitor cells.


**FIGURE 1A**



**FIGURE 1B**




# FIGURE 1C








**FIGURE 1D**




**FIGURE 2A**






Cells negative for 7-AAD



**FIGURE 2B**


**FIGURE 2C**




## FIGURE 3A



**FIGURE 3B**



**FIGURE 3C**



# FIGURE 3D

D






# FIGURE 3E



E



Sham procedure




Myocardial infarction




CD34 +

FIGURE 4D




SVEC

FIGURE 4C



CD34 -


FIGURE 4B



CD34 +

FIGURE 4A

## FIGURE 4E



# FIGURE 4F

F





FIGURE 5A



17/50

FIGURE 5B






FIGURE 5C



**FIGURE 5D**



## FIGURE 6A



## FIGURE 6B




## FIGURE 6C




## FIGURE 6D




# FIGURE 6E



## FIGURE 6F




## FIGURE 6G




**FIGURE 7A**

Flk-1




CD34pos/CD117 bright


GATA-2




GATA-3



AC 133




VWF




CD34pos/CD117 bright


eNOS



CD62 E




CXCR-1




CD34pos/CD117 bright

CXCR-2



CXCR-4



Log fluorescence

Relative cell number



## FIGURE 7B









FIGURE 7C



**FIGURE 8A**


**FIGURE 8B**

# FIGURE 8C





**FIGURE 8D**

IL-8/GRO-alpha protein




**FIGURE 8E**





**FIGURE 9A**




**FIGURE 9B**




## FIGURE 9C




**FIGURE 9D**





**FIGURE 10A**




**FIGURE 10B**

**FIGURE 10C**




**FIGURE 10D**

**FIGURE 11A**





**FIGURE 11B**



# FIGURE 11C








FIGURE 11D



# CC Chemokine Data

Fig. 12








Fig. 14




Fig. 15

## SEQUENCE LISTING

<110> SILVIU, ITESCU

<120> IDENTIFICATION AND USE OF HUMAN BONE MARROW-DERIVED ENDOTHELIAL PROGENITOR CELLS TO IMPROVE MYOCARDIAL FUNCTION AFTER ISCHEMIC INJURY

<130> 61697-a-pct

<160> 6

<170> PatentIn version 3.0

<210> 1

<211> 20

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<221> misc\_feature

<222> ()..()

<223> PRIMER

<400> 1

gaagatagat tgcaccgatg

20

<210> 2

<211> 18

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<221> misc\_feature

<222> ()..()

<223> PRIMER

<400> 2

catagcctct cacatttc

18

<210> 3

<211> 25

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<221> misc\_feature

<222> ()..()

<223> PRIMER

<400> 3

gcgcccgtcc gccaatgagc tgcg

25



<210> 4  
<211> 28  
<212> DNA  
<213> ARTIFICIAL SEQUENCE

<220>  
<221> misc\_feature  
<222> ()..()  
<223> PRIMER

<400> 4  
cttggggaca cccttcagca tcttttgg

28

<210> 5  
<211> 21  
<212> DNA  
<213> ARTIFICIAL SEQUENCE

<220>  
<221> misc\_feature  
<222> ()..()  
<223> PRIMER

<400> 5  
ctctacccac ggcaagttca a

21

<210> 6  
<211> 20  
<212> DNA  
<213> ARTIFICIAL SEQUENCE

<400> 6  
gggatgacct tgcccacagc

20

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/18399

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(7) : C07K 17/00; C12N 5/06; A61K 35/34 US CL : 530/351; 435/335,343; 424/569 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 530/351; 435/335,343; 424/569 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ASAHARA, T. et al. Bone Marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization, Circulation Research. 06 August 1999, Vol 85, pages 221-228, see entire document.	1-26, 61 and 62
X	US 5,980,887 A (ISNER et al) 09 November 1999 (9.11.1999), see entire document	1-26, 61 and 62
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
Special categories of cited documents:		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed	
Date of the actual completion of the international search 22 August 2001 (22.08.2001)		Date of mailing of the international search report 18 OCT 2001
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230		Authorized officer Jegatheesan Scharasoyan Telephone No. 703-308-0196

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/18399

### Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:  
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-26, 61 and 62

Remark on Protest

☐  
☐

- The additional search fees were accompanied by the applicant's protest.  
No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/18399

### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-26, 61 and 62, drawn to the special technical feature of a method for stimulating vasculogenesis.

Group II, claim(s) 27, 63 and 64, drawn to the special technical feature of a method for stimulating angiogenesis.

Group III, claim(s) 28-39, drawn to the special technical feature of a method for increasing the trafficking of endothelial progenitor cells.

Group IV, claim(s) 40-41, drawn to the special technical feature of a method for reducing the trafficking of endothelial progenitor cells.

Group V, claim(s) 42-43 and 59-60 in part, drawn to the special technical feature of a method for treating a cancer in a subject comprising administering to the subject a monoclonal antibody, wherein the subject is a mammal or human

Group VI, claim(s) 44-46 and 59-60 in part, drawn to the special technical feature of a method for treating a tumor in a subject comprising administering to the subject an antagonist to a specific receptor, wherein the subject is a mammal or human

Group VII, claim(s) 47-51, drawn to the special technical feature of a method of expressing a gene of interest in endothelial progenitor cells or mast progenitor cells.

Group VIII, claim(s) 52, drawn to the special technical feature of a composition comprising an amount of a monoclonal antibody.

Group IX, claim(s) 53-57, drawn to the special technical feature of a method for treating an abnormality in a subject by expressing GATA-2 activated gene product.

Group X, claim(s) 58 and 65-68, drawn to the special technical feature of a method for improving myocardial function in a subject.

The inventions listed as Groups I-X do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Claims 1-26, 61 and 62 lack an inventive step over Asahara et al. Consequently, the special technical feature which links Groups I to Group X, does not provide contribution over the prior art, so the unity of invention is lacking. Invention I - VII, IX and X are different from each other as they are directed to non equivalent methods. Invention I is a method for stimulating vasculogenesis. Invention II is a method for stimulating angiogenesis. Invention III is a method for increasing the trafficking of endothelial progenitor cells. Invention IV is of a method for reducing the trafficking of endothelial progenitor cells. Invention V is a method for treating a cancer in a subject comprising administering to the subject a monoclonal antibody. Invention VI is a method for treating a tumor in a subject comprising administering to the subject an antagonist to a specific receptor. Invention VII is a method of expressing a gene of interest in endothelial progenitor cells or mast progenitor cells. Invention IX is of a method for treating an abnormality in a subject by expressing GATA-2 activated gene product. Invention X is a method for improving myocardial function in a subject. Invention VIII is directed to a composition comprising a monoclonal antibody.

The claims of these groups are directed to different inventions which are not linked to form a single general inventive concept under PCT Rule 13.1. The claims in the different groups lack the same or corresponding special technical features. In particular, each group is directed to different compounds and/or methods. Accordingly, the claims are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept and lack of unity is deemed proper.

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US01/18399

**Continuation of B. FIELDS SEARCHED Item 3:**

**STN search on MEDLINE, BIOSIS, CAPLUS**

**WEST Search on USPAT, USPG, JPO**

**Search terms: Stem cells, endothelial cells, progenitor cells, vasculogenesis, cardiac damage and myocardium**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**